Antibody ID	ANI0ZCCGZ
Antibody Name	Undisclosed
Antigen Name	Undisclosed					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Patients Enrolled	Key eligibility: Adults (≥18) with progressive advanced sarcoma/prostate/breast/ovarian/pancreatic cancers (ECOG ≤2, life expectancy ≥6 months) post ≥1 prior therapy. Requires ACT Tumor Board recommendation, adequate organ function (ANC ≥1,500/uL, platelets ≥100,000/uL, bilirubin ≤1.5×ULN), and measurable disease. Major exclusions: active secondary malignancies, untreated CNS metastases, uncontrolled comorbidities (NYHA III-IV heart failure, severe infections), pregnancy/breastfeeding, or conditions jeopardizing protocol compliance.    Click to Show/Hide
Administration Dosage	Administered in monotherapy or in combination with other targeted agents or immunotherapies, chemotherapies, or radiation. Combination treatment plans may include a two-week monotherapy lead-in, followed by a combination treatment regimen. Each ACT study intervention must have an established RP2D determined in a prior clinical trial. Participants undergo a Pre-Treatment Biopsy, plus an On-Treatment Biopsy after two weeks on first dose of study drug (s) and prior to starting Cycle 2, regardless of regimen. Participants continue to receive study agent (s) after the On-Treatment Biopsy, according to the biopsy results and the results of ongoing safety and clinical assessments. Treatment cycles repeat every 21 to 28 days in the absence of disease progression or unacceptable toxicity. Cycles are determined based on the study agent (s). Upon disease progression, participants are given the option to undergo an additional biopsy.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT05238831	Clinical Status	EARLY_PHASE1
Clinical Description	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)
Primary Endpoint	Primary endpoint evaluates feasibility of ACT therapy implementation, requiring ≥11/15 participants (80%) to initiate recommended regimen within 2 years, with protocol-specified analysis of barriers if threshold unmet.
Other Endpoint	Secondary objectives assess safety (CTCAE v5.0-graded AEs, discontinuation rates), efficacy (6-month ORR by RECIST 1.1/pseudoprogression criteria), and survival outcomes (PFS, disease-specific survival, OS) through 5-year follow-up using Kaplan-Meier/cumulative incidence methods.
Experiment 2 Reporting the Activity Date of This ADC					[2]
Patients Enrolled	Key eligibility: Adults (&ge;18) with HER2+ (IHC3+/FISH+) metastatic breast cancer (1-3 prior lines, ECOG 0-1). Exclusions: prior HER2-ADC use, active CNS metastases (except stable treated lesions), uncontrolled effusions/ILD, significant cardiac disease, QTc risks, active infections (HBV/HCV/HIV), or pregnancy. Requires adequate organ function (ANC &ge;1.0&times;10<sup>9</sup>/L, LVEF >50%) and measurable disease (RECIST 1.1).    Click to Show/Hide
Administration Dosage	FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.
Related Clinical Trial
NCT Number	NCT05755048	Clinical Status	PHASE3
Clinical Description	A Multicenter, Open-label, Randomized Controlled Phase III Clinical Study to Compare the Efficacy and Safety of FS-1502 Versus T-DM1 in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Primary Endpoint	Primary endpoint evaluates PFS by independent central review (up to 28 months) in HER2+ metastatic breast cancer patients post-trastuzumab/taxane treatment, defined as time from enrollment to disease progression (≥20% target lesion increase per RECIST 1.1) or death.
Other Endpoint	Secondary objectives assess OS (time to death), ORR (confirmed CR+PR rates), DCR (CR+PR+SD), CBR (response lasting ≥24 weeks), DOR (response duration), and treatment-emergent AEs (NCI-CTCAE v5.0 graded) over 28 months.
Experiment 3 Reporting the Activity Date of This ADC					[3]
Patients Enrolled	Key eligibility: Adults (&ge;18) with untreated HER2+ (IHC3+) metastatic breast cancer (ECOG 0-1, LVEF &ge;50%), no prior systemic therapy except THP within 6 weeks. Exclusions: prior invasive breast cancer treatment, uncontrolled cardiac/ILD conditions, active infections (unless controlled HIV/HBV/HCV), CYP2C8/3A4 modifiers use, or pregnancy. Requires adequate organ function and stable brain metastases if present.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT06439693	Clinical Status	PHASE2
Clinical Description	A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study:
Primary Endpoint	Primary endpoint evaluates 4-year Disease-Free Survival (DFS4) using Kaplan-Meier method in HER2+ metastatic breast cancer patients, measuring time from registration to disease progression/death/anti-cancer therapy resumption (excluding endocrine therapy), with censoring at last evaluation for progression-free survivors.
Other Endpoint	Secondary objectives assess median Overall Survival (OS), Objective Response Rate (ORR by RECIST 1.1), Grade 3-5 treatment-related toxicity (CTCAE v5.0), completion rates of sequential therapy parts (A: taxane/trastuzumab/pertuzumab; B: trastuzumab deruxtecan; C: T-DM1/tucatinib; D: trastuzumab/pertuzumab/tucatinib), and DFS4 by Minimal Residual Disease status over 54 months.    Click to Show/Hide
Experiment 4 Reporting the Activity Date of This ADC					[2]
Patients Enrolled	Eligible patients (&ge;18 years) must have HER2+ disease (IHC3+ or IHC2+/FISH+), 1-3 prior lines (including adjuvant trastuzumab/taxane), ECOG 0-1, LVEF>50%, and adequate organ function. Key exclusions: prior HER2-ADC use, uncontrolled CNS metastases (unless stable &ge;6 months post-treatment), QTc prolongation risks, active HBV/HCV/HIV, or unresolved toxicity >CTCAE G1 (except alopecia/stable G2 neuropathy).    Click to Show/Hide
Administration Dosage	Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.
Related Clinical Trial
NCT Number	NCT05755048	Clinical Status	PHASE3
Clinical Description	A Multicenter, Open-label, Randomized Controlled Phase III Clinical Study to Compare the Efficacy and Safety of FS-1502 Versus T-DM1 in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Primary Endpoint	The study evaluates PFS by ICR in HER2+ unresectable/metastatic breast cancer patients previously treated with trastuzumab/taxanes over 28 months, with PD defined as ≥20% target lesion increase per RECIST v1.1.
Other Endpoint	Key efficacy endpoints (OS, ORR, DCR, CBR, DOR) and safety (TEAEs per NCI-CTCAE v5.0) are assessed via ICR/investigator over 28 months, with ORR requiring confirmed CR/PR (CR=target lesion disappearance; PR=≥30% decrease).
Experiment 5 Reporting the Activity Date of This ADC					[4]
Patients Enrolled	Eligible patients (&ge;18 years) have HER2+ advanced cancers (IHC3+ or IHC2+/FISH+), ECOG 0-1, LVEF>50%, with &ge;2 prior anti-HER2 lines. Key exclusions: CNS metastases, recent major surgery/RT (<4 weeks), QTc >470ms, active HBV/HCV/HIV, or unresolved toxicity >CTCAE G1 (except stable G2 alopecia/neuropathy). Tissue confirmation is mandatory for pivotal study participants.    Click to Show/Hide
Administration Dosage	Phase Ia: Patients enrolled on the 1.2 and 2.0 regimens: FS-1502 monotherapy every 4 weeks with intravenous drip, 28 days as a cycle; Patients enrolled on the 3.0 regimens: starting from the 1.0mg/kg dose group, FS-1502 monotherapy every 3 weeks with intravenous drip, 21 days as a cycle; Phase Ib: FS-1502 monotherapy, the dose and frequency of administration for Stage Ib will be obtained according to Phase Ia (RP2D).    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT03944499	Clinical Status	PHASE1
Clinical Description	A Phase I,Multicenter,Open-label,Single-arm Study:A Dose-escalation Phase Evaluating FS1502 in Patients With HER2 Expressed Advanced Solid Tumors,and a Dose-expanded Phase in Patients With Local Advanced or Metastatic,HER2+ Breast Cancer
Primary Endpoint	The Phase Ia study evaluates DLT (NCI-CTCAE v5.0) and determines MTD/RP2D for FS-1502. ORR (CR/PR per RECIST v1.1) is assessed by IRC in Phase Ib over ~2 years in HER2+ solid tumors with confirmed HER2 expression criteria.
Other Endpoint	Safety analyses include TEAEs (CTCAE v5.0), SAEs, and treatment discontinuations over ~3 years. Efficacy is measured by PFS (time to progression/death), OS (1-year rate), DOR (CR/PR to progression), and CBR (CR/PR/SD >6 mo). PK parameters (AUC, Cmax, tmax, T1/2, clearance) and anti-drug antibodies are also assessed.

Experiment 1 Reporting the Activity Date of This ADC					[5]
Patients Enrolled	Eligible subjects must be ≥18 years with measurable disease (RECIST 1.1), ECOG 0-1, and adequate organ function. Key exclusions include recent antitumor therapy (within 4 weeks/5 half-lives), prior topoisomerase I inhibitor ADC failure, planned antitumor therapy during study, or symptomatic CNS metastases.
Administration Dosage	Subjects will receive IBI129 on Day 1 of a 21-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and PK data), until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT05991349	Clinical Status	PHASE1|||PHASE2
Clinical Description	A Phase 1/2 Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors
Primary Endpoint	The study evaluates safety through adverse events (NCI CTCAE v5.0), physical exams, vital signs, and determines MTD/RP2D of IBI129 over 12-24 months.
Other Endpoint	Pharmacokinetic parameters (Cmax, AUC, Tmax, CL, V, T1/2) and immunogenicity of IBI129 are assessed over 12 months, while efficacy endpoints (ORR, DoR, DCR, TTR, PFS, OS) follow RECIST v1.1 criteria over 24 months.

Experiment 1 Reporting the Activity Date of This ADC					[6]
Patients Enrolled	Eligible subjects must be ≥18 years with advanced solid tumors (RECIST 1.1 measurable), ECOG 0-1, and adequate organ function. Key exclusions include cardiac dysfunction (NYHA II-IV, recent MI/unstable angina), active autoimmune/inflammatory diseases, uncontrolled infections, HIV/HBV/HCV, pregnancy/lactation, or unwillingness to use contraception.    Click to Show/Hide
Administration Dosage	Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 1 on Day 1 of each cycle Q3W
Related Clinical Trial
NCT Number	NCT05785728	Clinical Status	PHASE1|||PHASE2
Clinical Description	Phase 1/2, Multicenter, Open-label, First-in-human Study of DB-1202 Monotherapy in Patients With Advanced Solid Malignant Tumors to Evaluate the Tolerability, Safety, Pharmacokinetics and Antitumor Activity
Primary Endpoint	The study evaluates safety through DLTs (21 days post-Cycle 1), TEAEs/SAEs (CTCAE v5.0) over 1 year, and determines MTD/RP2D of DB-1202 in Phase 1, while Phase 2a assesses TEAEs/SAEs and ORR (RECIST 1.1) over 1 year.
Other Endpoint	Pharmacokinetic parameters (AUC, Cmax, Tmax, T1/2) of DB-1202 are analyzed within 8 treatment cycles (21-day cycles) across both Phase 1 and Phase 2a.
Experiment 2 Reporting the Activity Date of This ADC					[8]
Related Clinical Trial
NCT Number	NCT05785728	Clinical Status	Phase 1/2
Clinical Description	Phase 1/2, multicenter, open-label, first-in-human study of DB-1202 monotherapy in patients with advanced solid malignant tumors to evaluate the tolerability, safety, pharmacokinetics and antitumor activity.

Experiment 1 Reporting the Activity Date of This ADC					[7]
Patients Enrolled	Inclusion criteria include: age ≥18, life expectancy ≥6 months, informed consent, measurable disease by RECIST v1.1, ECOG 0-1, and adequate organ function. Part B requires Tissue Factor (TF)-positive tumors via IHC. Exclusions involve: TF-negative tumors (Part B), unresolved toxicities (>Grade 1), active CNS metastases, recent anticancer therapy (≤21 days), bleeding/cardiac risks, uncontrolled infections, pregnancy, HIV/hepatitis, strong CYP3A4 modifiers use, or conditions deemed unsafe by investigators. Prior radiotherapy toxicities must resolve to Grade ≤1.    Click to Show/Hide
Administration Dosage	All patients in Part A (dose escalation) and Part B (dose expansion) will be administrated MRG004A on Day 1 of every 3 weeks (21-day cycle).
Related Clinical Trial
NCT Number	NCT04843709	Clinical Status	PHASE1|||PHASE2
Clinical Description	An Open-Label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Primary Endpoint	The primary endpoints for this study include determining the Maximum Tolerated Dose (MTD) (assessed within the first 21-day treatment cycle) as the highest dose where <33% of patients experience Dose-Limiting Toxicity (DLT), and establishing the Recommended Phase II Dose (RP2D) based on safety, efficacy, and PK data (evaluated over 24 months). Additional metrics are Objective Response Rate (ORR) (CR+PR rate by Independent Central Review) and Adverse Events (AEs) (recorded from informed consent until 45 days post-last dose), covering all trial-related side effects regardless of causality.    Click to Show/Hide
Other Endpoint	Key secondary outcomes encompass efficacy measures: Duration of Response (DoR) (time from initial response to progression/death), Disease Control Rate (DCR) (CR+PR+SD≥6 weeks), Progression-Free Survival (PFS) (time to progression/death), and Overall Survival (OS) (time to death from any cause), all tracked for up to 24 months. Pharmacokinetic parameters (Cmax, Tmax, AUClast) and Anti-Drug Antibody (ADA) incidence are evaluated from baseline to 30 days post-treatment.    Click to Show/Hide

Experiment 1 Reporting the Activity Date of This ADC					[9]
Efficacy Data	Objective Response Rate (ORR)	21%
Patients Enrolled	Eligible participants have ECOG 0-1, adequate organ function, QTc ≤450/470 msec (M/F), and measurable disease (RECIST 1.1/RANO). Parts 1-4 include R/R SCLC/CNS tumors/NECs progressing after SOC. Exclusions: ILD/pneumonitis, prior Top1-ADC therapy, or (Part 2) prior SEZ6-ADC. Fresh/archival tumor tissue is required for SEZ6 analysis.
Administration Dosage	ABBV-706 was administered IV at 1.3-3.5 mg/kg doses Q3W in 21-d cycles.
Related Clinical Trial
NCT Number	NCT05599984	Clinical Status	PHASE1
Clinical Description	A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors
Primary Endpoint	Primary outcomes include AE incidence, PK parameters (Cmax, Tmax, t½, AUC), immunogenicity (ADA/nAb incidence), and tumor response metrics (ORR per RECIST 1.1/RANO, DOR, PFS, OS) assessed over ~2 years. The RP2D will be determined based on safety, PK, and efficacy data.

Experiment 1 Reporting the Activity Date of This ADC					[10]
Patients Enrolled	Eligible participants must provide informed consent, have histologically confirmed extensive-stage SCLC progressing after platinum therapy (≤3 prior metastatic regimens), be ≥18 years with ECOG 0-1, possess ≥1 RECIST-measurable lesion, provide tumor tissue (fresh or archived), and demonstrate >3 month life expectancy. Prior therapies must meet specified washout periods before enrollment.    Click to Show/Hide
Administration Dosage	Dose level 1 of ZL-1310 established from single-agent dose-escalation
Related Clinical Trial
NCT Number	NCT06179069	Clinical Status	PHASE1
Clinical Description	An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Small Cell Lung Cancer
Primary Endpoint	Safety endpoints include incidence of Dose Limiting Toxicities (DLTs), Treatment-Emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs) for ZL-1310 as monotherapy and in combination with atezolizumab ± carboplatin, all assessed over 24 months. DLTs will be evaluated separately for each treatment regimen (monotherapy, doublet, and triplet combinations), with corresponding counts of affected subjects recorded for each safety parameter.    Click to Show/Hide
Other Endpoint	Efficacy measures comprise ORR, DOR, PFS, DCR (all per RECIST 1.1), and OS for all three treatment regimens (monotherapy, doublet, triplet), evaluated over 24 months. Pharmacokinetic analyses include total antibody and unconjugated payload measurements for each treatment combination, with assessments continuing through the 24-month study period.

Experiment 1 Reporting the Activity Date of This ADC					[11]
Patients Enrolled	Key eligibility: Adults with progressive CRC/ovarian/endometrial/cervical/NSCLC cancers after ≥1 prior therapy, measurable disease, ECOG 0-1. Major exclusions: prior topoisomerase-1 ADC treatment, uncontrolled CNS metastases, Grade >1 residual toxicity, active infections/NIP-ILD, or recent anticancer therapies/surgeries.
Administration Dosage	PHN-010 is administered intravenously.
Related Clinical Trial
NCT Number	NCT06457997	Clinical Status	PHASE1
Clinical Description	First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients with Advanced Solid Tumors
Primary Endpoint	Primary endpoints include DLT incidence (Phase 1a, 18 months), AE/SAE monitoring (Phase 1a/1b, 18 months), dose modification frequency (18 months), and ORR assessment (Phase 1b, 36 months) in advanced solid tumors.
Other Endpoint	Secondary objectives encompass efficacy measures (BOR, DCR, PFS, TTR, OS, CA-125 response, 36 months), comprehensive PK analysis (Cmax/Tmax/AUC/t1/2 for ADC components, 36 months), and immunogenicity (ADA concentration, 36 months).

Experiment 1 Reporting the Activity Date of This ADC					[12]
Patients Enrolled	Inclusion: Signed consent, age ≥18, ECOG 0-2 (lymphoma) or 0-1 (solid tumors), life expectancy ≥3 months, measurable lesions, adequate organ function, contraception use. Exclusion: CNS/brain metastases, GVHD ≥G2, active infections, uncontrolled effusions, severe comorbidities, pregnancy, or conditions compromising study integrity per investigator judgment.    Click to Show/Hide
Administration Dosage	In dose escalation phase, participants will be administered escalating doses of HDM2005 at 0.3~2.75mg/kg IV on Day 1 of repeated 21-day cycles. In dose expansion phase, participants will be administered to recommended dose for expansion (RDE) of HDM2005 on Day 1 of repeated 21-day cycles .
Related Clinical Trial
NCT Number	NCT06615193	Clinical Status	PHASE1
Clinical Description	A Phase Ia/Ib, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Primary Endpoint	The dose escalation phase evaluates DLT incidence (21-day post-first dose) and AE severity (28-day post-last dose) per NCI CTCAE v5.0. The expansion phase assesses ORR (CR/PR, up to 3.5 years) and RP2D determination based on safety, PK, exposure-response, and efficacy data.
Other Endpoint	Pharmacokinetics include plasma concentrations of HDM2005, total antibody, and free MMAE (28-day post-last dose). Immunogenicity measures ADA-positive patients. Safety (AE monitoring) and efficacy endpoints (ORR, TTR, PFS, DOR, OS) are tracked for both phases over ~3.5 years.

Experiment 1 Reporting the Activity Date of This ADC					[13]
Patients Enrolled	Histologically or cytologically confirmed advanced TNBC that is relapsed, refractory, or progressive and not eligible for another standard therapy that would confer clinical benefit to the subject.
Administration Dosage	SC-005 intravenous (IV) (various doses and dose regimens)
Related Clinical Trial
NCT Number	NCT03316794	Clinical Status	PHASE1
Clinical Description	An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Primary Endpoint	Number of Participants with Dose-limiting Toxicities (DLTs) [Time Frame: Minimum 21 days]
Other Endpoint	QTcF Change from Baseline [Time Frame: Up to approximately 9 weeks]; Area Under the Plasma Concentration-time Curve (AUC); Clinical benefit rate (CBR); Maximum plasma concentration observed (Cmax); Overall Survival (OS); Observed Plasma Concentrations at Trough; Duration of Clinical Benefit (DOCB)

Experiment 1 Reporting the Activity Date of This ADC					[14]
Patients Enrolled	Key eligibility: Adults (≥18) with platinum-refractory HNSCC/cuSCC having accessible superficial lesions (≤1cm depth), measurable disease (RECIST 1.1), ECOG 0-2. Major exclusions: recent anticancer therapies (2 weeks/5 half-lives), active infections (HIV/HBV/HCV), QTc-prolonging medications, uncontrolled comorbidities, or hypersensitivity to antibody components. Tumor specimens required for pathology confirmation.    Click to Show/Hide
Administration Dosage	RM-1995 will be administered by intravenous (IV) infusion followed approximately 24 hours later by tumor illumination with 690 nm non thermal red light using the PIT690 Laser System. The starting dose of RM-1995 will be 0.25 mg/kg and escalated up to 2.0 mg/kg over 6 dosing cohorts
Related Clinical Trial
NCT Number	NCT05220748	Clinical Status	PHASE1
Clinical Description	A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma
Primary Endpoint	Primary endpoints focus on safety evaluation (DLTs, AEs) and dose determination (MTD/MAD) for RM-1995 PIT monotherapy (Phase 1a) and combination therapy with pembrolizumab (Phase 1b) over 24 months in recurrent HNSCC/cuSCC patients.
Other Endpoint	Secondary objectives include PK analysis (RM-1995, total antibody, IR-700 concentrations) during treatment cycles and antitumor activity assessment (ORRPIT by RECIST 1.1/irRECIST) over 24 months.
Experiment 2 Reporting the Activity Date of This ADC					[23]
Related Clinical Trial
NCT Number	NCT05220748	Clinical Status	Phase 1
Clinical Description	A phase 1 first-in-human, drug-dose escalation study of RM-1995 photoimmunotherapy, as monotherapy or combined with pembrolizumab, in patients with advanced cutaneous squamous cell carcinoma or with head and neck squamous cell carcinoma.

Experiment 1 Reporting the Activity Date of This ADC					[15]
Patients Enrolled	Key eligibility: Adults (≥18) with specified advanced solid tumors (including urothelial, G/GEJ/E, SCCHN, ovarian, PDAC, etc.), ECOG 0-1, adequate organ function (ANC >1,500/ul, platelets >100,000/ul, bilirubin ≤ULN). Major exclusions: prior docetaxel (6 months), active bleeding disorders, CNS metastases, strong CYP3A inhibitors use, grade ≥2 neuropathy, or anticoagulation therapy (except aspirin). Requires accessible tumor for biopsy and recovery from prior treatments (CTCAE v4.03 grade ≤1).    Click to Show/Hide
Administration Dosage	MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.
Related Clinical Trial
NCT Number	NCT03076372	Clinical Status	PHASE1
Clinical Description	A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors
Primary Endpoint	Primary objective is to determine the MTD of MM-310 monotherapy administered every 3 weeks in metastatic solid tumor patients over an 18-month evaluation period.
Other Endpoint	Secondary endpoints include serum drug level analysis, AE assessment (NCI-CTCAE v4.03), immunogenicity (anti-drug antibodies), and efficacy measures (ORR/DCR by RECIST v1.1, PFS) all monitored over 18 months.
Experiment 2 Reporting the Activity Date of This ADC					[22]
Related Clinical Trial
NCT Number	NCT03076372	Clinical Status	Phase 1
Clinical Description	A phase-1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[16]
Patients Enrolled	Eligible patients have HER2-positive unresectable/metastatic solid tumors (Part A: all types; Part B: breast/GEA) refractory to prior therapies, measurable/evaluable lesions (RECIST 1.1), ECOG ≤1, and adequate organ function. Exclusions include active CNS metastases, uncontrolled comorbidities, significant cardiovascular disease, or concurrent infections (HBV/HCV/HIV).    Click to Show/Hide
Administration Dosage	The assigned dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle).
Related Clinical Trial
NCT Number	NCT04029922	Clinical Status	PHASE1
Clinical Description	A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors
Primary Endpoint	The primary objectives are to assess the safety and tolerability of MT-5111 by monitoring adverse events (CTCAE v5.0) and dose-limiting toxicities (DLTs) to determine the MTD/RP2D over 21-day cycles.
Other Endpoint	Secondary objectives include evaluating MT-5111 pharmacokinetics (Cmax, Tmax, AUC) on Days 1/8/15 per cycle, tumor response (ORR per RECIST 1.1), and immunogenicity (ADA/NAb titers) at baseline, treatment cycles, and follow-up.
Experiment 2 Reporting the Activity Date of This ADC					[17]
Patients Enrolled	Eligible participants must be enrolled in MT-5111_001 with ≥1 measurable lesion (RECIST 1.1; osteosarcoma exceptions permitted), have recent/planned FDG-PET/CT, and be capable of PET/CT imaging. Exclusions include hepatic-only disease and pregnancy/breastfeeding status.
Related Clinical Trial
NCT Number	NCT04757090	Clinical Status	PHASE2
Clinical Description	A Pilot Study of 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
Primary Endpoint	The primary imaging endpoint is the average 89Zr-trastuzumab SUVmax (maximum standardized uptake value) in lesions identified on baseline FDG-PET/CT scans.
Other Endpoint	Secondary imaging analyses include average 89Zr-trastuzumab tumor-to-normal tissue and tumor-to-blood uptake ratios, along with intra-patient heterogeneity assessment (fractions of scan-positive/negative lesions) in multi-lesion cases.

Experiment 1 Reporting the Activity Date of This ADC					[18]
Patients Enrolled	Eligible patients have advanced CRC (≥2 prior metastatic regimens, including pembrolizumab for MSI-H) or gastric cancer (≥2 prior lines, including HER2-targeted therapy if applicable), with ECOG 0-1 and adequate organ function. Exclusions include significant comorbidities, uninterpretable QTc, and prior exposure to PBD/indolinobenzodiazepine drugs.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT03253185	Clinical Status	PHASE1
Clinical Description	An Open Label Study of SC-007 in Subjects With Advanced Cancer
Primary Endpoint	The primary safety endpoint is the incidence of dose-limiting toxicities (DLTs) during the first treatment cycle (up to 21 days), graded per NCI CTCAE v4.03 criteria.
Other Endpoint	Key efficacy measures include clinical benefit rate (CBR=CR+PR+SD), progression-free survival (PFS), and overall survival (OS) over 4 years. Pharmacokinetic parameters (Cmax, Tmax, AUC, T1/2, Ctrough) and QTcF changes are monitored for 1 year, while anti-drug antibodies (ATAs) and objective response metrics (ORR, DOR) are tracked for 4 years.
Experiment 2 Reporting the Activity Date of This ADC					[21]
Patients Enrolled	Patients with advanced cancer (Colorectal Cancer or Gastric Cancer).
Administration Dosage	SC-007 iv.
Related Clinical Trial
NCT Number	NCT03253185	Clinical Status	Phase 1
Clinical Description	An open label study of SC-007 in subjects with advanced cancer.

Experiment 1 Reporting the Activity Date of This ADC					[19]
Patients Enrolled	Eligible patients must have metastatic/unresectable solid tumors (measurable per RECIST 1.1), ≥1 prior systemic therapy, ECOG 0-1, and adequate organ function. Key exclusions include active CNS metastases (unless stable post-radiation), uncontrolled cardiac conditions, prior toxin-directed therapy, or hypersensitivity to dCD133KDEL components. Women of childbearing potential must use dual contraception.    Click to Show/Hide
Administration Dosage	Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
Related Clinical Trial
NCT Number	NCT02845414	Clinical Status	PHASE1
Clinical Description	Phase I Study Of Stem-Cell Directed Deimmunized CD133KDEL Toxin In The Treatment Of Solid Tumors
Primary Endpoint	The primary objective is to determine the maximum tolerated dose (MTD) of dCD133KDEL by Day 28, with dose-limiting toxicities (DLTs) defined as ≥Grade 3 adverse events (CTCAE v4.0) within 21 days post-first dose that are possibly treatment-related.
Other Endpoint	Secondary objectives include tumor response assessment per RECIST 1.1 criteria (evaluated between Days 29-33 and every 6-12 weeks thereafter), with responses summarized by dose level including 95% confidence intervals.

Experiment 1 Reporting the Activity Date of This ADC					[20]
Patients Enrolled	Eligible patients must be ≥18 years with ECOG ≤2; Phase 1a requires advanced epithelial solid tumors (failed prior chemo), Phase 1b requires recurrent/metastatic gastric cancer (chemo-naïve or failed prior chemo), with adequate organ function and life expectancy ≥3 months. Exclusions include CNS metastases, recent chemo/radiation/surgery, active infections, uncontrolled diabetes, significant cardiac history, or concurrent investigational therapies.    Click to Show/Hide
Administration Dosage	Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks; Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
Related Clinical Trial
NCT Number	NCT01466569	Clinical Status	PHASE1
Clinical Description	A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors
Primary Endpoint	Safety evaluation includes adverse events (AEs), clinical lab tests, and physical exams over 10 weeks, focusing on treatment-emergent AEs and their severity.
Other Endpoint	Pharmacokinetic analysis at 3 dose levels (Phase 1a) and 2 dose levels (Phase 1b), with immunogenicity assessment (anti-drug antibodies) and tumor response per RECIST criteria, monitored over 10-12 weeks

Experiment 1 Reporting the Activity Date of This ADC					[24]
Patients Enrolled	This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).
Related Clinical Trial
NCT Number	NCT05365659	Clinical Status	Phase 1
Clinical Description	This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 13.33%	Positive CD46 expression (CD46 +++/++)
Method Description	In vivo efficacy of PNU-conjugated ADCs in NSCLC LU253 PDX subcutaneous models in NOD/SCID mice. A single dose of 1.0 mg/kg HuIgG1-19 ADC.
In Vivo Model	Non-small cell lung cancer PDX model (PDX: LU253 PDX)
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 21.34%	Positive CD46 expression (CD46 +++/++)
Method Description	In vivo efficacy of PNU-conjugated ADCs in colorectal CR188 PDX subcutaneous models in NOD/SCID mice. A single dose of 1.0 mg/kg HuIgG1-19 ADC.
In Vivo Model	Colorectal cancer PDX model (PDX: CR188 PDX)

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 3 nM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Uterine sarcoma	MES-SA cells		CVCL_1404
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.8 nM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 56.63%	Positive EGFR expression (EGFR+++/++)
Method Description	PDX mice were administrated vehicle or DTLL at the LDMequivalent dose of 0.1 mg/kg once a week for 3 wk. Tumor volumes were measured after animals were sacrificed on Days 24 and 39, respectively. DTLL was administered via tail vein injection once a week for three weeks.
In Vivo Model	Pancreatic cancer PDX model (PDX: PA1338)

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 14.30%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	IGROV-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 19.40%	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Tumor Growth Inhibition value (TGI)	30%	High FOLR1 expression (FOLR1+++; 4,500,000 FOLR1 molecules/cell)
Method Description	Animals with established tumors of about 130 mm3 were treated with intravenous single injection of the M9346A-DM conjugates at 50 mg/kg, equivalent to 82 g conjugated maytansinoid per kg The conjugates were injected on day 4 after cell inoculation.
In Vivo Model	FRalpha-positive KB CDX model
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 32.80%	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 37.80%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 44%	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 55.20%	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 78.40%	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 55.55%
Method Description	C57BL/6-albino mice were subcutaneously inoculated with 5x105 MC38 on the right flank. Once the tumors had reached an average volume of approximately 125 mm3 as determined by measuring with a caliper, the mice were randomly divided into groups after which 100 g AU-011 in 100 uL was administered intravenously into the tail vein or intraperitoneally, or 30 g AU-011 in 30 L was administered intratumorally.    Click to Show/Hide
In Vivo Model	MC38 CDX model
In Vitro Model	Mouse colon adenocarcinoma	MC-38 cells		CVCL_B288

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 57.10%	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	IGROV-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 85.70%	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	IGROV-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 57.11%
Method Description	The inhibitory activity of 1B-3R conjugate against cancer cell growth was evaluated in various human cancer cell lines in vivo.
In Vivo Model	Colorectal cancer CDX model
In Vitro Model	Colorectal cancer	Colorectal cancer cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 57.90%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 95%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 67.80%	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 1.5 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 6 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 3 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 70.60%	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 74.20%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 0.5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 93.50%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 87.50%	Positive PSMA expression (PSMA +++/++)
Method Description	In order to specify the pharmacological properties of MMAE.VC.SA.617 we inoculated LNCaP cells into NOD/SCID mice to generate a xenograft model. In vivo therapeutic efficacy studies were conducted with MMAE.VC.SA.617, namely 1.0 mg/kg (corresponding to 0.49 mg MMAE).
In Vivo Model	LNCaP CDX model
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.10%	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 1.5 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 6 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 3 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.57%	High LGALS3BP expression (LGALS3BP +++)
Method Description	Gch6 cell xenograft mice were intravenously treated with 10 mg/kg 1959-sss/DM4 twice weekly for a total of three injections.
In Vivo Model	Gch6 CDX model
In Vitro Model	Glioblastoma	Gch6 cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.02 nM	High LGALS3BP expression (LGALS3BP +++)
Method Description	In vitro cytotoxicity of ADCs against a panel of four multiple human glioblastoma cell lines.
In Vitro Model	Glioblastoma	Gch14 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.57 nM	High LGALS3BP expression (LGALS3BP +++)
Method Description	In vitro cytotoxicity of ADCs against a panel of four multiple human glioblastoma cell lines.
In Vitro Model	Glioblastoma	Gch6 cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 100%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 100%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 0.5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 56.70%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 15.20%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 16.70%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 94.70%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 16.70%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 21.70%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 64.60%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 70.20%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 87.30%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 87.40%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15.8 pM	Positive CCR4 expression (CCR4 +++/++)
Method Description	In vitro efficacy comparison of the CCR4 IT vs IL2 fusion toxin to human CCR4+ CTCL Hut102/6TG using luminescent cell viability assay.
In Vitro Model	Cutaneous T cell lymphoma	HUT102/6TG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	30.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	48.2 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28.1 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	57.8 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	112 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28.3 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	51.6 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	107 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	31.6 pM	Positive CCR4 expression (CCR4 +++/++)
Method Description	In vitro efficacy comparison of the CCR4 IT vs IL2 fusion toxin to human CCR4+ CTCL Hut102/6TG using luminescent cell viability assay.
In Vitro Model	Cutaneous T cell lymphoma	HUT102/6TG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	34.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	73.3 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	178 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	37.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	60 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	211 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	41.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	598 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.01 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	45.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	73.2 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	165 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	46.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	67.1 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	371 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	47.9 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	92.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	426 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	50.8 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	79.8 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	247 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	53.2 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	54.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	98.3 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	53.8 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	61.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	117 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	54.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	55.1 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	77.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	66.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	72.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.38 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	67.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	75.1 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	74.3 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	219 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	79 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	294 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	79.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	189 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	114 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	156 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	158 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	131 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	137 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	153 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	156 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	170 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	184 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	218 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	225 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.29 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	356 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	405 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	370 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	509 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	485 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	740 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.52 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	47 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.13 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.23 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.21 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.15 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.13 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	61 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.15 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.15 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.18 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.18 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.29 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	12 nM	Positive CD22 expression (CD22+++/++)
Method Description	Each ADC dilution was dispensed into 4 replicate wells of the 96-well plate, containing cell suspension. Control wells received the same volume of culture medium only. After incubation for 4 days, cell viability was measured by either Alamar blue or MTS assay.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18 nM	Positive CD22 expression (CD22+++/++)
Method Description	Each ADC dilution was dispensed into 4 replicate wells of the 96-well plate, containing cell suspension. Control wells received the same volume of culture medium only. After incubation for 4 days, cell viability was measured by either Alamar blue or MTS assay.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	23 nM	Positive CD22 expression (CD22+++/++)
Method Description	Each ADC dilution was dispensed into 4 replicate wells of the 96-well plate, containing cell suspension. Control wells received the same volume of culture medium only. After incubation for 4 days, cell viability was measured by either Alamar blue or MTS assay.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	23 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	34 nM	High EGFR expression (EGFR+++)
Method Description	The effect of MMAE-conjugated cetuximab ADCs on the viability of U87 glioblastoma cells that express EGFR.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Effective Concentration (EC50)	25 pM	Positive CLL-1 expression (CLL-1+++/++)
Method Description	In vitro cytotoxicity of the anti-hCLL-1 ARC-ADCs was then evaluated using human AML cell lines U937 (CLL-1+) and KG1a (CLL-1-1).
In Vitro Model	Adult acute monocytic leukemia	U-937 cells		CVCL_0007

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 pM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Normal	HEK293T cells		CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 3 nM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Uterine sarcoma	MES-SA cells		CVCL_1404

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1000 pM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Uterine sarcoma	MES-SA cells		CVCL_1404
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.1 nM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.4 nM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Uterine sarcoma	MES-SA cells		CVCL_1404
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 nM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	-0.70%	Positive TPBG expression (TPBG+++/++)
Method Description	The patient-derived tumor firagments (2mmx2mmx2mm,TPBG positive cells constituted 58.86% and MET positive cells constituted 24.08% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 3mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 28.    Click to Show/Hide
In Vivo Model	TPBG Patient-derived Xenograft Model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	9.30%
Method Description	Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 1x106 (NCI-H1975) tumor cells, and treatmen with 1.5mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 28.
In Vivo Model	NCI-H1975 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	11.30%
Method Description	The patient-derived tumor firagments (2mmx2mmx2mm) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 3mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 28.
In Vivo Model	TPBG Patient-derived Xenograft Model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	61.9 ug/ml
Method Description	Series diluted ADCs (maximum concentration: 20 ug/mL, 3-fold dilutions, 10 gradients)were used to treat human lung squamous carcinoma NCI-H226 5000cells cultured in a cellculture plate, and the killing activity was detected after 72 hours of incubation in IncuCyte (Sartorius AG, IncuCytee S3).
In Vitro Model	Pleural epithelioid mesothelioma	NCI-H226 cells		CVCL_1544

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	28.90%	Positive TPBG expression (TPBG+++/++)
Method Description	The patient-derived tumor firagments (2mmx2mmx2mm,TPBC positive cells constituted 19.5% of total cells and MET positive cells constituted 8.3% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 1.5mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 45.    Click to Show/Hide
In Vivo Model	TPBG Patient-derived Xenograft Model
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	60.70%	Positive TPBG expression (TPBG+++/++)
Method Description	The patient-derived tumor firagments (2mmx2mmx2mm,TPBC positive cells constituted 19.5% of total cells and MET positive cells constituted 8.3% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 3mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 45.    Click to Show/Hide
In Vivo Model	TPBG Patient-derived Xenograft Model
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	64.50%	Positive TPBG expression (TPBG+++/++)
Method Description	The patient-derived tumor firagments (2mmx2mmx2mm,TPBG positive cells constituted 58.86% and MET positive cells constituted 24.08% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 3mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 28.    Click to Show/Hide
In Vivo Model	TPBG Patient-derived Xenograft Model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	87.70%
Method Description	Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 1x106 (NCI-H1975) tumor cells, and treatmen with 3mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 28.
In Vivo Model	NCI-H1980 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	94.50%
Method Description	Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 5x106 (NUGC-4) tumor cells, and treatmen with 3mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 35.
In Vivo Model	NUGC-6 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.9855 ug/ml
Method Description	Series diluted ADCs (maximum concentration: 20 ug/mL, 3-fold dilutions, 10 gradients)were used to treat human lung squamous carcinoma NCI-H226 5000cells cultured in a cellculture plate, and the killing activity was detected after 72 hours of incubation in IncuCyte (Sartorius AG, IncuCytee S3).
In Vitro Model	Pleural epithelioid mesothelioma	NCI-H226 cells		CVCL_1544

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	29.20%	Positive TPBG expression (TPBG+++/++)
Method Description	The patient-derived tumor firagments (2mmx2mmx2mm,TPBC positive cells constituted 19.5% of total cells and MET positive cells constituted 8.3% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 1.5mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 45.    Click to Show/Hide
In Vivo Model	TPBG Patient-derived Xenograft Model
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	62.90%	Positive TPBG expression (TPBG+++/++)
Method Description	The patient-derived tumor firagments (2mmx2mmx2mm,TPBC positive cells constituted 19.5% of total cells and MET positive cells constituted 8.3% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 3mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 45.    Click to Show/Hide
In Vivo Model	TPBG Patient-derived Xenograft Model
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	96.40%	Positive TPBG expression (TPBG+++/++)
Method Description	The patient-derived tumor firagments (2mmx2mmx2mm,TPBG positive cells constituted 58.86% and MET positive cells constituted 24.08% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 3mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 28.    Click to Show/Hide
In Vivo Model	TPBG Patient-derived Xenograft Model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	57%
Method Description	Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 1x106 (NCI-H1975) tumor cells, and treatmen with 1.5mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 28.
In Vivo Model	NCI-H1977 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	87.60%
Method Description	Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 5x106 (NUGC-4) tumor cells, and treatmen with 3mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 35.
In Vivo Model	NUGC-5 xenograft model
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	91.90%
Method Description	Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 1x106 (NCI-H1975) tumor cells, and treatmen with 3mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 28.
In Vivo Model	NCI-H1979 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.5044 ug/ml
Method Description	Series diluted ADCs (maximum concentration: 20 ug/mL, 3-fold dilutions, 10 gradients)were used to treat human lung squamous carcinoma NCI-H226 5000cells cultured in a cellculture plate, and the killing activity was detected after 72 hours of incubation in IncuCyte (Sartorius AG, IncuCytee S3).
In Vitro Model	Pleural epithelioid mesothelioma	NCI-H226 cells		CVCL_1544

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	45%	Positive TPBG expression (TPBG+++/++)
Method Description	The patient-derived tumor firagments (2mmx2mmx2mm,TPBC positive cells constituted 19.5% of total cells and MET positive cells constituted 8.3% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 3mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 45.    Click to Show/Hide
In Vivo Model	TPBG Patient-derived Xenograft Model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	64.90%
Method Description	Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 1x106 (NCI-H1975) tumor cells, and treatmen with 3mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 28.
In Vivo Model	NCI-H1980 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.533 ug/ml
Method Description	Series diluted ADCs (maximum concentration: 20 ug/mL, 3-fold dilutions, 10 gradients)were used to treat human lung squamous carcinoma NCI-H226 5000cells cultured in a cellculture plate, and the killing activity was detected after 72 hours of incubation in IncuCyte (Sartorius AG, IncuCytee S3).
In Vitro Model	Pleural epithelioid mesothelioma	NCI-H226 cells		CVCL_1544

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	45.90%	Positive TPBG expression (TPBG+++/++)
Method Description	The patient-derived tumor firagments (2mmx2mmx2mm,TPBG positive cells constituted 58.86% and MET positive cells constituted 24.08% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 3mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 28.    Click to Show/Hide
In Vivo Model	TPBG Patient-derived Xenograft Model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	59.20%
Method Description	Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 1x106 (NCI-H1975) tumor cells, and treatmen with 1.5mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 28.
In Vivo Model	NCI-H1976 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	97.70%
Method Description	Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 5x106 (NUGC-4) tumor cells, and treatmen with 3mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 35.
In Vivo Model	NUGC-4 xenograft model
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	98.70%
Method Description	Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 1x106 (NCI-H1975) tumor cells, and treatmen with 3mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 28.
In Vivo Model	NCI-H1978 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	54.50%
Method Description	B-NDG mice were engrafted in the right flank with gastric cancer patient-derived tumortissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPBG-positive cells and MET-positive cells in the gastric tumor fragments were 10.1 1% and 1.19%, respectively, When the tumors in the mice reached a volume of about 200-300 mm3, the mice were randomly placed into different groups based on the tumor volume. The mice werethen injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 35.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	80.20%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 19.54% and 8.31%, respectively. When the tumors in the mice reached a volume of about 200-300 mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 3mg/kg ADC's by i.v, BIW, administration. Determined tumor volume after the experiment, measured at day 32.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	84.30%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 31.01% and 76.96%, respectively. When the tumors in the mice reached a volume of about 200-300mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 25.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	57.90%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 19.54% and 8.31%, respectively. When the tumors in the mice reached a volume of about 200-300 mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 3mg/kg ADC's by i.v, BIW, administration. Determined tumor volume after the experiment, measured at day 32.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	63.10%
Method Description	B-NDG mice were engrafted in the right flank with gastric cancer patient-derived tumortissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPBG-positive cells and MET-positive cells in the gastric tumor fragments were 10.1 1% and 1.19%, respectively, When the tumors in the mice reached a volume of about 200-300 mm3, the mice were randomly placed into different groups based on the tumor volume. The mice werethen injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 35.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	80.40%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 31.01% and 76.96%, respectively. When the tumors in the mice reached a volume of about 200-300mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 25.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	90.90%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 19.54% and 8.31%, respectively. When the tumors in the mice reached a volume of about 200-300 mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 3mg/kg ADC's by i.v, BIW, administration. Determined tumor volume after the experiment, measured at day 32.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	91.50%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 58.86% and 24.08%, respectively. When the tumors in the mice reached a volume of about 150-200 mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 25.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model

Experiment 1 Reporting the Activity Date of This ADC					[41]
Efficacy Data	Tumor Growth lnhibition value (TGl)	71.59%	Positive FR-alpha expression (FR-alpha+++/++)
Method Description	In the OV3756 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
In Vivo Model	OV3756 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[41]
Efficacy Data	Tumor Growth lnhibition value (TGl)	71.59%	Positive FR-alpha expression (FR-alpha+++/++)
Method Description	In the OV3756 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
In Vivo Model	OV3756 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	72.10%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 31.01% and 76.96%, respectively. When the tumors in the mice reached a volume of about 200-300mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 25.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model

Experiment 1 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth lnhibition value (TGl)	77.29%
Method Description	The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
In Vivo Model	NSCLC cancer PDX model LU-01-1618
Experiment 2 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth lnhibition value (TGl)	0.97%
Method Description	The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
In Vivo Model	IGROV1 tumor xenograft model
Experiment 3 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth lnhibition value (TGl)	1.00%
Method Description	The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
In Vivo Model	IGROV1 tumor xenograft model
Experiment 4 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth lnhibition value (TGl)	105.97%
Method Description	The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
In Vivo Model	NSCLC cancer PDX model LU-01-1618
Experiment 5 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth lnhibition value (TGl)	111.94%
Method Description	The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
In Vivo Model	NSCLC cancer PDX model LU-01-1618
Experiment 6 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth lnhibition value (TGl)	116.16%
Method Description	The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
In Vivo Model	NSCLC cancer PDX model LU-01-1618
Experiment 7 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth lnhibition value (TGl)	116.16%
Method Description	The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
In Vivo Model	IGROV1 tumor xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.55 nM	High IGROV1 expression (IGROV1 +++)
Method Description	IC50 Values (nM) of anti-FOLR1-151-K-LOCK-D5 and their corresponding controls in Human Tumor Cells IGROV1.
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	15 nM	Low SKOV-3 expression ( SKOV-3 +)
Method Description	IC50 Values (nM) of anti-FOLR1-151-K-LOCK-D5 and their corresponding controls in Human Tumor Cells SKOV-3
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	78.50%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 31.01% and 76.96%, respectively. When the tumors in the mice reached a volume of about 200-300mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 25.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	79.80%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 58.86% and 24.08%, respectively. When the tumors in the mice reached a volume of about 150-200 mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 25.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	80.80%
Method Description	B-NDG mice were engrafted in the right flank with gastric cancer patient-derived tumortissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPBG-positive cells and MET-positive cells in the gastric tumor fragments were 10.1 1% and 1.19%, respectively, When the tumors in the mice reached a volume of about 200-300 mm3, the mice were randomly placed into different groups based on the tumor volume. The mice werethen injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 35.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	86.70%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 19.54% and 8.31%, respectively. When the tumors in the mice reached a volume of about 200-300 mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 3mg/kg ADC's by i.v, BIW, administration. Determined tumor volume after the experiment, measured at day 32.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	90.50%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 31.01% and 76.96%, respectively. When the tumors in the mice reached a volume of about 200-300mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 25.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	92.50%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 58.86% and 24.08%, respectively. When the tumors in the mice reached a volume of about 150-200 mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 25.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	85.40%
Method Description	B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 58.86% and 24.08%, respectively. When the tumors in the mice reached a volume of about 150-200 mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 25.    Click to Show/Hide
In Vivo Model	Patient-derived Xenograft B-NDG mice Model

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Tumor Growth lnhibition value (TGl)	87.39%
Method Description	When the tumor diameter reached 1.00 cm, qualified cynomolgus monkey liver cancer models were selected and randomly divided into an ADC intravenous injection 0.2 mg kg-1 group (n = 3), an ADC intravenous injection 1.0 mg kg-1 group (n = 3), and a physiological saline control group (n = 2). The ADC was administered once a week for 8 weeks. Tumor volumes were observed by ultrasound scans, and Figure 3C shows representative photos of ultrasound scans before and after the 8-week ADC treatment,0.2 mg/kg.    Click to Show/Hide
In Vivo Model	CRISPR-Mediated Cynomolgus Monkey Liver Cancer Model
Experiment 2 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Tumor Growth lnhibition value (TGl)	91.11%
Method Description	When the tumor diameter reached 1.00 cm, qualified cynomolgus monkey liver cancer models were selected and randomly divided into an ADC intravenous injection 0.2 mg kg-1 group (n = 3), an ADC intravenous injection 1.0 mg kg-1 group (n = 3), and a physiological saline control group (n = 2). The ADC was administered once a week for 8 weeks. Tumor volumes were observed by ultrasound scans, and Figure 3C shows representative photos of ultrasound scans before and after the 8-week ADC treatment,1 mg/kg.    Click to Show/Hide
In Vivo Model	CRISPR-Mediated Cynomolgus Monkey Liver Cancer Model

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	35.97 nM	High CD147 expression (CD147 +++)
Method Description	Human HCC cell lines HCC-LM3, MHCC97-H, and Huh-7 were seeded in 96-well plates (3000 cells per well). After the cells had adhered to the walls, different concentration gradients of Mehozumab-DM1 diluent, Mehozumab diluent, and IgG were added, and the cells were cultured in a 37 °C incubator under 5% CO2 for 72 h. ThenCCK8 (cat#: C005; Topscience Biology) was used to determine cell viability. Per the manufacturer's instructions, 10 uL of CCK8 reagent was added to each well followed by incubation for 1 h. The absorbance was measured at 450 nm, and used to calculate the corresponding IC50 value using GraphPad Prism v8.0 software (GraphPad Software Inc., San Diego, CA).    Click to Show/Hide
In Vitro Model	Adult hepatocellular carcinoma	HCC-LM3 cells		CVCL_6832
Experiment 2 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	83.07 nM	High CD147 expression (CD147 +++)
Method Description	Human HCC cell lines HCC-LM3, MHCC97-H, and Huh-7 were seeded in 96-well plates (3000 cells per well). After the cells had adhered to the walls, different concentration gradients of Mehozumab-DM1 diluent, Mehozumab diluent, and IgG were added, and the cells were cultured in a 37 °C incubator under 5% CO2 for 72 h. ThenCCK8 (cat#: C005; Topscience Biology) was used to determine cell viability. Per the manufacturer's instructions, 10 uL of CCK8 reagent was added to each well followed by incubation for 1 h. The absorbance was measured at 450 nm, and used to calculate the corresponding IC50 value using GraphPad Prism v8.0 software (GraphPad Software Inc., San Diego, CA).    Click to Show/Hide
In Vitro Model	Adult hepatocellular carcinoma	MHCC97-H cells		CVCL_E3I0
Experiment 3 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	367.1 nM	Moderate CD147 expression (CD147++)
Method Description	Human HCC cell lines HCC-LM3, MHCC97-H, and Huh-7 were seeded in 96-well plates (3000 cells per well). After the cells had adhered to the walls, different concentration gradients of Mehozumab-DM1 diluent, Mehozumab diluent, and IgG were added, and the cells were cultured in a 37 °C incubator under 5% CO2 for 72 h. ThenCCK8 (cat#: C005; Topscience Biology) was used to determine cell viability. Per the manufacturer's instructions, 10 uL of CCK8 reagent was added to each well followed by incubation for 1 h. The absorbance was measured at 450 nm, and used to calculate the corresponding IC50 value using GraphPad Prism v8.0 software (GraphPad Software Inc., San Diego, CA).    Click to Show/Hide
In Vitro Model	Adult hepatocellular carcinoma	Huh-7 cells		CVCL_0336

Experiment 1 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth lnhibition value (TGl)	95.31%
Method Description	Discovered Using Cell Line-derived IGROV1 tumor xenograft model in 151-C-LOCK-D5 1.5 mg/kg.
In Vivo Model	IGROV1 tumor xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth lnhibition value (TGl)	100%
Method Description	Discovered Using Cell Line-derived IGROV1 tumor xenograft model in 151-C-LOCK-D5 1.5 mg/kg.
In Vivo Model	IGROV1 tumor xenograft model
Experiment 3 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth lnhibition value (TGl)	100%
Method Description	Discovered Using Cell Line-derived IGROV1 tumor xenograft model in 151-C-LOCK-D5 1.5 mg/kg.
In Vivo Model	IGROV1 tumor xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.35 nM	High IGROV1 expression (IGROV1 +++)
Method Description	IC50 Values (nM) of anti-FOLR1-151-C-LOCK-D5 and their corresponding controls in Human Tumor Cells IGROV1
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	45 nM	Low SKOV-3 expression ( SKOV-3+)
Method Description	IC50 Values (nM) of anti-FOLR1-151-C-LOCK-D5 and their corresponding controls in Human Tumor Cells SKOV-3
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth lnhibition value (TGl)	115.07%
Method Description	Inhibition Effect of ADC-1,3mg/kg on NCI-N87 CDX Mouse Model
In Vivo Model	NCI-N87 CDX Mouse Model

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.04636 nM
Method Description	Proliferation Inhibition Effect of Different Drugs on Tumor Cells (IC50, nM)in BT-474,
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.08706 nM
Method Description	Proliferation Inhibition Effect of Different Drugs on Tumor Cells (IC50, nM)in NCI-N87
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	25000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	29000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	15 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 4 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	170 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 5 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8100 ng/ml	Moderate 5T4 expression (5T4++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/5T4 (a high 5t4 expressor) and MDA-MB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	> 45000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	> 83000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	14 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 4 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	160 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 5 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13000 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	84000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	15 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 3 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	270 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 4 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	36000 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.002 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Colo205
In Vitro Model	Colon adenocarcinoma	Colo205 cells		CVCL_0218
Experiment 2 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on H2110
In Vitro Model	Lung non-small cell carcinoma	H2110 cells		CVCL_1530
Experiment 3 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Jeg3
In Vitro Model	Gestational choriocarcinoma	Jeg3 cells		CVCL_0363

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.174 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Jeg3
In Vitro Model	Gestational choriocarcinoma	Jeg3 cells		CVCL_0363
Experiment 2 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	11 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on H2110
In Vitro Model	Lung non-small cell carcinoma	H2110 cells		CVCL_1530
Experiment 3 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	50 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OVCAR-3
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	398 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OV90
In Vitro Model	Adenocarcinoma of ovary, Ovarian adenocarcinoma	OV90 cells		CVCL_3768

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.174 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Jeg3
In Vitro Model	Gestational choriocarcinoma	Jeg3 cells		CVCL_0363
Experiment 2 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	11 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on H2110
In Vitro Model	Lung non-small cell carcinoma	H2110 cells		CVCL_1530
Experiment 3 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	50 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OVCAR-3
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	398 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OV90
In Vitro Model	Adenocarcinoma of ovary, Ovarian adenocarcinoma	OV90 cells		CVCL_3768

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.18 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Jeg3
In Vitro Model	Gestational choriocarcinoma	Jeg3 cells		CVCL_0363

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.26 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Colo205
In Vitro Model	Colon adenocarcinoma	Colo205 cells		CVCL_0218

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.639 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Jeg3
In Vitro Model	Gestational choriocarcinoma	Jeg3 cells		CVCL_0363
Experiment 2 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on H2110
In Vitro Model	Lung non-small cell carcinoma	H2110 cells		CVCL_1530
Experiment 3 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OVCAR-3
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	138 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OV90
In Vitro Model	Adenocarcinoma of ovary, Ovarian adenocarcinoma	OV90 cells		CVCL_3768

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.639 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Jeg3
In Vitro Model	Gestational choriocarcinoma	Jeg3 cells		CVCL_0363
Experiment 2 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on H2110
In Vitro Model	Lung non-small cell carcinoma	H2110 cells		CVCL_1530
Experiment 3 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OVCAR-3
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	138 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OV90
In Vitro Model	Adenocarcinoma of ovary, Ovarian adenocarcinoma	OV90 cells		CVCL_3768

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Jeg3
In Vitro Model	Gestational choriocarcinoma	Jeg3 cells		CVCL_0363
Experiment 2 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	28 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on H2110
In Vitro Model	Lung non-small cell carcinoma	H2110 cells		CVCL_1530

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	190 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Jeg3
In Vitro Model	Gestational choriocarcinoma	Jeg3 cells		CVCL_0363
Experiment 2 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	70000 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OVCAR-3
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	100000 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OV90
In Vitro Model	Adenocarcinoma of ovary, Ovarian adenocarcinoma	OV90 cells		CVCL_3768
Experiment 4 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	500000 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on H2110
In Vitro Model	Lung non-small cell carcinoma	H2110 cells		CVCL_1530

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	214.4 pM	Positive CD45 expression (CD45+++/++)
Method Description	Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.    Click to Show/Hide
In Vitro Model	Acute erythroid leukemia	OCIM1 cells		CVCL_2149
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	309.6 pM	Positive CD45 expression (CD45+++/++)
Method Description	Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.    Click to Show/Hide
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 3 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 6000 pM	Negative CD45 expression (CD45-)
Method Description	Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.    Click to Show/Hide
In Vitro Model	Normal	293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2288.3 pM	Positive CD45 expression (CD45+++/++)
Method Description	Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.    Click to Show/Hide
In Vitro Model	Acute erythroid leukemia	OCIM1 cells		CVCL_2149
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3399.8 pM	Positive CD45 expression (CD45+++/++)
Method Description	Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.    Click to Show/Hide
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 3 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 6000 pM	Negative CD45 expression (CD45-)
Method Description	Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.    Click to Show/Hide
In Vitro Model	Normal	293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4800 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Jeg3
In Vitro Model	Gestational choriocarcinoma	Jeg3 cells		CVCL_0363

Experiment 1 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.006 nM
Method Description	IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in CML-T1 TRBC1
In Vitro Model	Chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	CML-T1 TRBC1 cells		CVCL_1126
Experiment 2 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.009 nM
Method Description	IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in HPB-ALL TRBC2
In Vitro Model	Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia	HPB-ALL TRBC2 cells		CVCL_1820
Experiment 3 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.012 nM
Method Description	IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in SUP-T1 TRBC1
In Vitro Model	Childhood T lymphoblastic lymphoma, T-cell non-Hodgkin lymphoma	SUP-T1 TRBC1 cells		CVCL_1714
Experiment 4 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.014 nM
Method Description	IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in Jurkat TCR-KO
In Vitro Model	Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia	Jurkat TCR-KO cells		CVCL_0065
Experiment 5 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.016 nM
Method Description	IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in H9 TRBC1
In Vitro Model	Sezary syndrome	H9 TRBC1 cells		CVCL_1240
Experiment 6 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.016 nM
Method Description	IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in HPB-ALL TRBC1
In Vitro Model	Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia	HPB-ALL TRBC1 cells		CVCL_1820
Experiment 7 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.025 nM
Method Description	IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in Jurkat TRBC1
In Vitro Model	Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia	Jurkat TRBC1 cells		CVCL_0065
Experiment 8 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.03 nM
Method Description	IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in Jurkat TRBC2
In Vitro Model	Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia	Jurkat TRBC2 cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[49]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.02 nM	Positive HER2 expression (HER2+++/++)
Method Description	HT29 cells were plated at a density of 5000 cells per well and the next day were treated with antibody-PBD conjugate for 3 days.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[49]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.21 nM	Positive HER2 expression (HER2+++/++)
Method Description	DLD1 cells were plated at a density of 5000 cells per well and the next day were treated with antibody-PBD conjugate for 3 days.
In Vitro Model	Colon adenocarcinoma	DLD1 cells		CVCL_0248

Experiment 1 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.075 nM	Positive ICAM-1 expression (ICAM-1+++/++)
Method Description	Cells from triple-negative breast cancer were propagated in slides with 96 chambers, each well containing 5000 cells. The medium was replaced with medium supplemented with nanoparticle Nab PTX, IgG-Dxd, or ICAM-1-Dxd at various concentrations. After 72 h, the toxic effects on the cells were assessed via a CCK-8 test. In brief, the medium containing the pharmaceuticals was discarded, and the cells were carefully rinsed with chilled PBS. The samples were subsequently incubated in a CCK-8 solution maintained at 37 °C for 4 h. The degree to which cell growth was suppressed was determined by comparing the optical density of agent-exposed cells to that of untreated control cells. In addition, extracellular ATP concentrations were quantified via a Beyotime ATP detection kit (S0026).    Click to Show/Hide
In Vitro Model	Mammary carcinoma	4T1 cells		CVCL_0125
Experiment 2 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.132 nM	Positive ICAM-1 expression (ICAM-1+++/++)
Method Description	Cells from triple-negative breast cancer were propagated in slides with 96 chambers, each well containing 5000 cells. The medium was replaced with medium supplemented with nanoparticle Nab PTX, IgG-Dxd, or ICAM-1-Dxd at various concentrations. After 72 h, the toxic effects on the cells were assessed via a CCK-8 test. In brief, the medium containing the pharmaceuticals was discarded, and the cells were carefully rinsed with chilled PBS. The samples were subsequently incubated in a CCK-8 solution maintained at 37 °C for 4 h. The degree to which cell growth was suppressed was determined by comparing the optical density of agent-exposed cells to that of untreated control cells. In addition, extracellular ATP concentrations were quantified via a Beyotime ATP detection kit (S0026).    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.141 nM	Positive ICAM-1 expression (ICAM-1+++/++)
Method Description	Cells from triple-negative breast cancer were propagated in slides with 96 chambers, each well containing 5000 cells. The medium was replaced with medium supplemented with nanoparticle Nab PTX, IgG-Dxd, or ICAM-1-Dxd at various concentrations. After 72 h, the toxic effects on the cells were assessed via a CCK-8 test. In brief, the medium containing the pharmaceuticals was discarded, and the cells were carefully rinsed with chilled PBS. The samples were subsequently incubated in a CCK-8 solution maintained at 37 °C for 4 h. The degree to which cell growth was suppressed was determined by comparing the optical density of agent-exposed cells to that of untreated control cells. In addition, extracellular ATP concentrations were quantified via a Beyotime ATP detection kit (S0026).    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	BT-549 cells		CVCL_1092

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.106 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.106 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.241 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.638 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.114 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.114 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.256 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.17 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	322 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.123 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.123 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.216 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.648 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.125 nM
Method Description	IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in CML-T1 TRBC1
In Vitro Model	Chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	CML-T1 TRBC1 cells		CVCL_1126
Experiment 2 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.141 nM
Method Description	IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in Jurkat TRBC2
In Vitro Model	Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia	Jurkat TRBC2 cells		CVCL_0065
Experiment 3 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.144 nM
Method Description	IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in Jurkat TCR-KO
In Vitro Model	Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia	Jurkat TCR-KO cells		CVCL_0065
Experiment 4 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.145 nM
Method Description	IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in Jurkat TRBC1
In Vitro Model	Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia	Jurkat TRBC1 cells		CVCL_0065
Experiment 5 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.155 nM
Method Description	IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in HPB-ALL TRBC2
In Vitro Model	Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia	HPB-ALL TRBC2 cells		CVCL_1820
Experiment 6 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.156 nM
Method Description	IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in HPB-ALL TRBC1
In Vitro Model	Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia	HPB-ALL TRBC1 cells		CVCL_1820
Experiment 7 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.248 nM
Method Description	IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in SUP-T1 TRBC1
In Vitro Model	Childhood T lymphoblastic lymphoma, T-cell non-Hodgkin lymphoma	SUP-T1 TRBC1 cells		CVCL_1714
Experiment 8 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.611 nM
Method Description	IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in H9 TRBC1
In Vitro Model	Sezary syndrome	H9 TRBC1 cells		CVCL_1240

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.139 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.139 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.19 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.46 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	209 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.14 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.14 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.661 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.82 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.151 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.151 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.262 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.607 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.152 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.152 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.293 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.594 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.16 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.16 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.282 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.682 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	366 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.164 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.164 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.265 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.71 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	223 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.172 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.172 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.31 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.73 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.186 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.186 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.222 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.07 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.21 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.21 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.302 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.14 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	355 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.216 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.216 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.327 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.19 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.256 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.256 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.83 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10.4 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.303 nM	High HER2 expression (HER2 +++)
Method Description	The cell line used in the anti-proliferation assays was SK-BR-3, a human breast, adenocarcinoma (pleural effusion) cell line; The cells were grown in McCoy's 5a Medium+10% FBS. To run the assay, the cells (80 ul, 1000 cells) were added to each well in a 96-well plate and incubated for 24 hours at 37°C. with CO,. Next, the cells were treated with test compounds (20 ul) at various concentrations in appropriate cell culture medium (total volume, 0.1 mL). The control wells contain cells and the medium but lack the test compounds. The plates were incubated for 144 hours at 37°C. with CO,. CTG reagent was then added to the wells (100 il). After the plates were shaken for 10 min and then incubated for 10 min at room temperature, paste the clear bottom with white back seal and record luminescence with Envision. The inhibition % was calculated according to the following equation: inhibition %=[1- (assay-blank)/ (control-blank)|x100.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.303 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.581 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.04 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	81.6 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[53]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.69&#1770.31 nM
Method Description	Human thyroid cancer cells were seeded in a 96-well plate at a density of 3000 cells per well overnight. The cell culture medium was replaced with the medium containing either chemo drugs (maximum concentration: 117.11 umol/L) or ICAM1-ADCs at serial diluted concentrations (maximum concentration: 0.67 umol/L). After 96h, cell cytotoxicity was determined by using a CCK-8 kit (KeyGEN Biotech, China) following the manufacturer's protocol. The absorbance at 450 nm was measured with an ELISA browser (Bio-Tek EL 800, USA). The experiments were repeated three times.    Click to Show/Hide
In Vitro Model	Differentiated thyroid carcinoma, Thyroid gland papillary carcinoma	IHH4 cells		CVCL_2960
Experiment 2 Reporting the Activity Date of This ADC					[53]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.35&#1771.45 nM
Method Description	Human thyroid cancer cells were seeded in a 96-well plate at a density of 3000 cells per well overnight. The cell culture medium was replaced with the medium containing either chemo drugs (maximum concentration: 117.11 umol/L) or ICAM1-ADCs at serial diluted concentrations (maximum concentration: 0.67 umol/L). After 96h, cell cytotoxicity was determined by using a CCK-8 kit (KeyGEN Biotech, China) following the manufacturer's protocol. The absorbance at 450 nm was measured with an ELISA browser (Bio-Tek EL 800, USA). The experiments were repeated three times.    Click to Show/Hide
In Vitro Model	Thyroid gland anaplastic carcinoma	8505C cells		CVCL_1054
Experiment 3 Reporting the Activity Date of This ADC					[53]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	15.59&#1774.18 nM
Method Description	Human thyroid cancer cells were seeded in a 96-well plate at a density of 3000 cells per well overnight. The cell culture medium was replaced with the medium containing either chemo drugs (maximum concentration: 117.11 umol/L) or ICAM1-ADCs at serial diluted concentrations (maximum concentration: 0.67 umol/L). After 96h, cell cytotoxicity was determined by using a CCK-8 kit (KeyGEN Biotech, China) following the manufacturer's protocol. The absorbance at 450 nm was measured with an ELISA browser (Bio-Tek EL 800, USA). The experiments were repeated three times.    Click to Show/Hide
In Vitro Model	Thyroid gland anaplastic carcinoma, Anaplastic thyroid carcinoma	TCO1 cells		CVCL_M839
Experiment 4 Reporting the Activity Date of This ADC					[53]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	68.6&#17711.2 nM
Method Description	Human thyroid cancer cells were seeded in a 96-well plate at a density of 3000 cells per well overnight. The cell culture medium was replaced with the medium containing either chemo drugs (maximum concentration: 117.11 umol/L) or ICAM1-ADCs at serial diluted concentrations (maximum concentration: 0.67 umol/L). After 96h, cell cytotoxicity was determined by using a CCK-8 kit (KeyGEN Biotech, China) following the manufacturer's protocol. The absorbance at 450 nm was measured with an ELISA browser (Bio-Tek EL 800, USA). The experiments were repeated three times.    Click to Show/Hide
In Vitro Model	Thyroid carcinoma	BCPAP cells		CVCL_0153

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.365 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.0 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[53]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.48&#1770.88 nM
Method Description	Human thyroid cancer cells were seeded in a 96-well plate at a density of 3000 cells per well overnight. The cell culture medium was replaced with the medium containing either chemo drugs (maximum concentration: 117.11 umol/L) or ICAM1-ADCs at serial diluted concentrations (maximum concentration: 0.67 umol/L). After 96h, cell cytotoxicity was determined by using a CCK-8 kit (KeyGEN Biotech, China) following the manufacturer's protocol. The absorbance at 450 nm was measured with an ELISA browser (Bio-Tek EL 800, USA). The experiments were repeated three times.    Click to Show/Hide
In Vitro Model	Differentiated thyroid carcinoma, Thyroid gland papillary carcinoma	IHH4 cells		CVCL_2960
Experiment 2 Reporting the Activity Date of This ADC					[53]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	54.1&#17719.4 nM
Method Description	Human thyroid cancer cells were seeded in a 96-well plate at a density of 3000 cells per well overnight. The cell culture medium was replaced with the medium containing either chemo drugs (maximum concentration: 117.11 umol/L) or ICAM1-ADCs at serial diluted concentrations (maximum concentration: 0.67 umol/L). After 96h, cell cytotoxicity was determined by using a CCK-8 kit (KeyGEN Biotech, China) following the manufacturer's protocol. The absorbance at 450 nm was measured with an ELISA browser (Bio-Tek EL 800, USA). The experiments were repeated three times.    Click to Show/Hide
In Vitro Model	Thyroid carcinoma	BCPAP cells		CVCL_0153

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.05 nM	High CD48 expression (CD48 +++)
Method Description	lgG-P1-L12-P4 was tested in KMS-27
In Vitro Model	Plasma cell myeloma, Multiple myeloma	KMS-27 cells		CVCL_2993
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	20.47 nM	High CD48 expression (CD48 +++)
Method Description	lgG-P1-L12-P4 was tested in RL
In Vitro Model	Diffuse large B-cell lymphoma	RL cells		CVCL_1660
Experiment 3 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 50 nM	High CD48 expression (CD48 +++)
Method Description	lgG-P1-L12-P4 was tested in KHM-1B
In Vitro Model	Plasma cell myeloma, Multiple myeloma	KHM-1B cells		CVCL_2972

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.25 nM	Positive FR expression (FR+++/++)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	Negative FR expression (FR-)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.13 nM	Positive CD19 expression (CD19+++/++)
Method Description	Cells were treated with corresponding agents with various concentrations for 12 or 48 h, and cell viability was detected by MTT (C0009M, Beyotime) assay. Dose-response curves were fitted by GraphPad Prism 9 software. Then, IC50 values were calculated.
In Vitro Model	Normal	CHO cells (CD19+)		CVCL_0213
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	27.21 uM	Negative CD19 expression (CD19-)
Method Description	Cells were treated with corresponding agents with various concentrations for 12 or 48 h, and cell viability was detected by MTT (C0009M, Beyotime) assay. Dose-response curves were fitted by GraphPad Prism 9 software. Then, IC50 values were calculated.
In Vitro Model	Normal	CHO cells (CD19-)		CVCL_0213

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.37 nM	Positive FR expression (FR+++/++)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.03 nM	Negative FR expression (FR-)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.53 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.73 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	11.4 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	25.1 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	71.5 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	263 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13.3 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	24.6 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	49.3 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	19.47 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.096 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	21.1 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	31.5 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	51.69 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	109 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	24.505 nM	Positive FR expression (FR+++/++)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	36.665 nM	Negative FR expression (FR-)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	33.1 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	47.7 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	85.56 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	47.8 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	70.4 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	147.4 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	233 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on MDA-MB-468
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on SW-780
In Vitro Model	Mouse melanoma	SW-780 cells		CVCL_1728
Experiment 3 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	≈ 50≈200 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on MCF-7
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on LNCAP
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395
Experiment 5 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on BxPC-3
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on MDA-MB-468
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	≈ 50≈200 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on SW-780
In Vitro Model	Mouse melanoma	SW-780 cells		CVCL_1728
Experiment 3 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	≈ 50≈200 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on MCF-7
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on LNCAP
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395
Experiment 5 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on BxPC-3
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on MDA-MB-468
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on SW-780
In Vitro Model	Mouse melanoma	SW-780 cells		CVCL_1728
Experiment 3 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	≈ 50≈200 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on MCF-7
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on LNCAP
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395
Experiment 5 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on BxPC-3
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on MDA-MB-468
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on SW-780
In Vitro Model	Mouse melanoma	SW-780 cells		CVCL_1728
Experiment 3 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	≈ 50≈200 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on LNCAP
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395
Experiment 4 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on BxPC-3
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 5 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	≈ 200≈1000 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on MCF-7
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on MDA-MB-468
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on SW-780
In Vitro Model	Mouse melanoma	SW-780 cells		CVCL_1728
Experiment 3 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	≈ 50≈200 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on MCF-7
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on LNCAP
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395
Experiment 5 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 50 nM	High NECTIN4 expression (NECTIN4 +++)
Method Description	A Cell line test on BxPC-3
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	66.79 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	69.63 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.7102 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.9334 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	80.71 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	8.52 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	88.2 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	95.3 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 169 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	280 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	89.1 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	142 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	210 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	331 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[61]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	High C10orf54 expression (C10orf54 +++)
Method Description	C1.18 DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model	Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia	OCI/AML3 cells		CVCL_1844
Experiment 2 Reporting the Activity Date of This ADC					[61]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	High C10orf54 expression (C10orf54 +++)
Method Description	C1.18 DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model	Acute myeloid leukemia, Childhood acute myeloid leukemia	P31/FUJ cells		CVCL_1632
Experiment 3 Reporting the Activity Date of This ADC					[61]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	High C10orf54 expression (C10orf54 +++)
Method Description	C1.18 DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model	Acute promyelocytic leukemia	PL21 cells		CVCL_2161

Experiment 1 Reporting the Activity Date of This ADC					[62]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	Moderate TF expression (TF++)
Method Description	Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[62]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	Moderate TF expression (TF++)
Method Description	Pancreatic cancer cell lines HPAF-II, BxPC-3, or PSN-1 were harvested on 96-well plates (Corning) and incubated at 37°C overnight. Payloads and ADCs were applied to each well at various concentrations, and the plates were incubated at 37°C for 6 days (n = 3). Cancer cell viability was measured using CCK-8 (Dojindo).
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	105.8 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	115.4 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	112.1 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	118.4 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	121 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	341 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	121 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	184 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	156 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	273.3 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	174.3 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.275 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	178 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	204 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	187.3 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4826 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	195.6 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.14 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	212 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	229.6 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.7058 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	280.7 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5972 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	293.3 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.8 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	309.2 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	11.67 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 4 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	457.6 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	39.79 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	550.4 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	244.7 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	706.8 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	787.1 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	731.9 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	735.5 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	865 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	764.3 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	30.24 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	779.4 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.35 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	799.7 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	26.56 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	803.7 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.76 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	834.5 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	365.1 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.83 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4634 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.379 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.54 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.95 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1028 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	15.33 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.3 ng/mL	Positive TRBC1 expression (TRBC1+++/++)
Method Description	A total of 1 × 104 T cell cancer cells or the normal human T cells was suspended in 200 ul of RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin in 96-well flat-bottom tissue culture-treated plates. The following drugs were resuspended in DMSO solution to make a 10 mM stock solution; exatecan mesylate (MedChemExpress HY-13631A), DM1 (MedChemExpress HY-19792), SN38 (MedChemExpress HY-13704), MMAE (MedChemExpress HY-15162), SG3199 (MedChemExpress HY-101161). The drugs were added to the target cells at the concentrations specified in the text for 5 days at 37 °C. For luciferase-expressing cells, cell viability was assayed using the ONE-Glo luciferase assay (E6110, Promega) according to the manufacturer's instructions. Luminescence data were collected using the Synergy H1 microplate reader and analysed with the Biotek Gen5 software. Viability was calculated as the ratio of the luminescence signal to the no antibody or control antibody condition: (antibody well luminescence)/ (no antibody or control antibody well luminescence).    Click to Show/Hide
In Vitro Model	Sezary syndrome	H9 cells		CVCL_1240
Experiment 2 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.6 ng/mL	Positive TRBC1 expression (TRBC1+++/++)
Method Description	A total of 1 × 104 T cell cancer cells or the normal human T cells was suspended in 200 ul of RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin in 96-well flat-bottom tissue culture-treated plates. The following drugs were resuspended in DMSO solution to make a 10 mM stock solution; exatecan mesylate (MedChemExpress HY-13631A), DM1 (MedChemExpress HY-19792), SN38 (MedChemExpress HY-13704), MMAE (MedChemExpress HY-15162), SG3199 (MedChemExpress HY-101161). The drugs were added to the target cells at the concentrations specified in the text for 5 days at 37 °C. For luciferase-expressing cells, cell viability was assayed using the ONE-Glo luciferase assay (E6110, Promega) according to the manufacturer's instructions. Luminescence data were collected using the Synergy H1 microplate reader and analysed with the Biotek Gen5 software. Viability was calculated as the ratio of the luminescence signal to the no antibody or control antibody condition: (antibody well luminescence)/ (no antibody or control antibody well luminescence).    Click to Show/Hide
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.27 uM	High PD-L1 expression (PD-L1 +++)
Method Description	The cytotoxicity of SN38, IgG-NPLG-SN38 and aPDL1-NPLG-SN38 toward MC38 cells was evaluated using a CCK-8 assay. Specifically, the MC38 cells were seeded into 96-well plates (5 × 103 cells per well) and incubated overnight. SN38, IgG-NPLG-SN38 or aPDL1-NPLG-SN38 was then added at a range of concentrations (0.01-100 uM SN38) to each well and cultured for 72 h. CCK-8 reagent was then added to each well and incubated for 1 h, after which the plate was measured on a microplate reader at a wavelength of 450 nm. Cell viability was calculated from the ratio of optical density (OD) values of sample to control wells.    Click to Show/Hide
In Vitro Model	Mouse colon adenocarcinoma	MC38 cells		CVCL_B288

Experiment 1 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 uM	High PD-L1 expression (PD-L1 +++)
Method Description	The cytotoxicity of SN38, IgG-NPLG-SN38 and aPDL1-NPLG-SN38 toward MC38 cells was evaluated using a CCK-8 assay. Specifically, the MC38 cells were seeded into 96-well plates (5 × 103 cells per well) and incubated overnight. SN38, IgG-NPLG-SN38 or aPDL1-NPLG-SN38 was then added at a range of concentrations (0.01-100 uM SN38) to each well and cultured for 72 h. CCK-8 reagent was then added to each well and incubated for 1 h, after which the plate was measured on a microplate reader at a wavelength of 450 nm. Cell viability was calculated from the ratio of optical density (OD) values of sample to control wells.    Click to Show/Hide
In Vitro Model	Mouse colon adenocarcinoma	MC38 cells		CVCL_B288

Experiment 1 Reporting the Activity Date of This ADC					[65]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.5196 ug/mL
Method Description	The in vitro cytotoxicity of anti-PD-L1-PBA-Cur on colon cancer cells was investigated. The HCT116 cells were seeded at a density of 5 × 103 cells/well in a 96-well plate to attach overnight. After co-incubation with 48 h, the cell's viability was investigated using the MTT assay. The cell morphology was further observed using the microscopy.
In Vitro Model	Colon carcinoma	HCT116 cells		CVCL_0291

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0001 nM	Positive CD45 expression (CD45 +++/++)
Method Description	In vitro PBMC killing assays: ADCs conjugated to AM2
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Cyno PBMC	0.0001 nM	Positive CD45 expression (CD45 +++/++)
Method Description	In vitro PBMC killing assays: ADCs conjugated to AM2
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	280 pM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro BM HSC killing assay: ADCs conjugated to AM2
In Vitro Model	Bone marrow hematopoietic stem cells	BM HSC cells (CD34+CD90+)		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0005 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro PBMC killing assays: ADCs conjugated to AM2
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 3 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0008 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro PBMC killing assays: ADCs conjugated to AM2
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 4 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0173 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	in vitro PBMC killing assays: ADCs conjugated to AM1, PBD, or IGN
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 5 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.033 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell killing assays: ADCs conjugated to AM1, AM3, or PBD
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 6 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.12 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 7 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.16 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell killing assays: ADCs conjugated to AM1, AM2, or PBD
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 8 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.42 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 9 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.538 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	in vitro PBMC killing assays: ADCs conjugated to AM1, PBD, or IGN
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 10 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.6071 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0023 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro REH cell line killing assay - IC5S0O values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.13 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0037 nM	Positive CD45,Ab7 expression (CD45,Ab7 +++/++)
Method Description	In vitro cell line killing assay - IC52 values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.069 nM	Positive CD45,Ab7 expression (CD45,Ab7 +++/++)
Method Description	In vitro REH cell line killing assay - IC5S0O values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0055 nM	Positive CD45,Ab2 expression (CD45,Ab2 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0126 nM	Positive CD45,Ab2 expression (CD45,Ab2 +++/++)
Method Description	in vitro HSC PBMC killing assay (stimulated vs non-stimulated) IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 3 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.266 nM	Positive CD45,Ab2 expression (CD45,Ab2 +++/++)
Method Description	in vitro HSC PBMC killing assay (stimulated vs non-stimulated) IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0071 nM	Positive CD45,Ab3 expression (CD45,Ab3 +++/++)
Method Description	In vitro cell line killing assay - IC51 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.048 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro REH cell line killing assay - IC5S0O values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0085 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0085 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro human and cyno PBMC cell killing assay with Ab5-AM1 - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 3 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0091 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro human and cyno PBMC cell killing assay with Ab5-AM1 - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 4 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.043 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia	REH cells (CD45+)		CVCL_1650
Experiment 5 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.043 nM	Negative CD45 expression (CD45-)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia	REH cells (CD45-)		CVCL_1650
Experiment 6 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.091 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196
Experiment 7 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.49 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro human and cyno PBMC cell killing assay with Ab5-AM1 - IC50 values
In Vitro Model	Normal	PBMC cells (CD34+CD90+)		CVCL_0140
Experiment 8 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.58 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.011 nM	Positive CD45,Ab2 expression (CD45,Ab2 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.012 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro PBMC killing assays: ADCs conjugated to AM1
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.023 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro PBMC killing assays: ADCs conjugated to AM1
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 3 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.36 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 4 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.372 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro BM HSC killing assay: ADCs conjugated to AM1 or PBD
In Vitro Model	Bone marrow hematopoietic stem cells	BM HSC cells (CD34+CD90+)		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.71 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell killing assays: ADCs conjugated to AM1, AM2, or PBD
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 6 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	1.1 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 7 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	1.365 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.025 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.066 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia	REH cells (CD45+)		CVCL_1650
Experiment 3 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.066 nM	Negative CD45 expression (CD45-)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia	REH cells (CD45-)		CVCL_1650
Experiment 4 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.2378 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196
Experiment 5 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.38 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.026 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.28 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0294 nM	Positive CD34+,CD90+ expression (CD34+,CD90+ +++/++)
Method Description	In vitro BM HSC killing assay: ADCs conjugated to AM1 or PBD
In Vitro Model	Bone marrow hematopoietic stem cells	BM HSC cells (CD34+CD90+)		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.042 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 3 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.36 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 4 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.8185 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.03 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.04 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.042 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell killing assays: ADCs conjugated to AM1, AM4, or PBD
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 3 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.37 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 4 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.7142 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196
Experiment 5 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	53 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell killing assays: ADCs conjugated to AM1, AM4, or PBD
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.065 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell killing assays: ADCs conjugated to AM1, AM4, or PBD
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.42 nM	Positive CD45,AbC expression (CD45,AbC +++/++)
Method Description	In vitro cell killing assays: ADCs conjugated to AM1, AM4, or PBD
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.25 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	1 nM	Positive CD45,Ab3 expression (CD45,Ab3 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	1.69 nM	Positive CD34+,CD90+ expression (CD34+,CD90+ +++/++)
Method Description	In vitro BM HSC killing assay: ADCs conjugated to AM1 or PBD
In Vitro Model	Bone marrow hematopoietic stem cells	BM HSC cells (CD34+CD90+)		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	3.8 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 3 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	9.624 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196
Experiment 4 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	12 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	100 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro human and cyno PBMC cell killing assay with Ab5-AM1 - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.0003 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.003 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.004 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.005 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	< 0.005 nM
Method Description	Proliferation of AML cell lines in AML2 following treatment with ADCs, EC50 in mAb1-LD2
In Vitro Model	Adult acute myeloid leukemia, Acute myeloid leukemia with t(6;11)(q27;q23) KMT2A-MLLT4, Acute myeloid leukemia	AML2 cells		CVCL_1619
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.005 nM
Method Description	Proliferation of AML cell lines in MOLM13 following treatment with ADCs, EC50 in mAb1-LD2
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.005 nM
Method Description	Proliferation of AML cell lines in MV411 following treatment with ADCs, EC50 in mAb1-LD2
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	< 0.005 nM
Method Description	Proliferation of AML cell lines in AML2 following treatment with ADCs, EC50 in mAb1-LD3
In Vitro Model	Adult acute myeloid leukemia, Acute myeloid leukemia with t(6;11)(q27;q23) KMT2A-MLLT4, Acute myeloid leukemia	AML2 cells		CVCL_1619
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.005 nM
Method Description	Proliferation of AML cell lines in MOLM13 following treatment with ADCs, EC50 in mAb1-LD3
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	< 0.005 nM
Method Description	Proliferation of AML cell lines in MV411 following treatment with ADCs, EC50 in mAb1-LD3
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.039 nM
Method Description	Proliferation of AML cell lines in THP1 following treatment with ADCs, EC50 in mAb1-LD2
In Vitro Model	Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia	THP1 cells		CVCL_0006
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.073 nM
Method Description	Proliferation of AML cell lines in THP1 following treatment with ADCs, EC50 in mAb1-LD3
In Vitro Model	Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia	THP1 cells		CVCL_0006
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.29 nM
Method Description	Proliferation of AML cell lines in MV411 following treatment with ADCs, EC50 in mAb3-LD3
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12.29 nM
Method Description	Proliferation of AML cell lines in AML2 following treatment with ADCs, EC50 in mAb3-LD3
In Vitro Model	Adult acute myeloid leukemia, Acute myeloid leukemia with t(6;11)(q27;q23) KMT2A-MLLT4, Acute myeloid leukemia	AML2 cells		CVCL_1619
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	14.38 nM
Method Description	Proliferation of AML cell lines in MOLM13 following treatment with ADCs, EC50 in mAb3-LD3
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 12 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20.27 nM
Method Description	Proliferation of AML cell lines in THP1 following treatment with ADCs, EC50 in mAb3-LD3
In Vitro Model	Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia	THP1 cells		CVCL_0006

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.008 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.008 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	H1048 cells		CVCL_1453
Experiment 2 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.018 nM	High B7H3 expression (B7H3 +++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Minimally invasive lung adenocarcinoma	H358 cells		CVCL_1559
Experiment 3 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.291 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung papillary adenocarcinoma	H441 cells		CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Negative B7H3 expression (B7H3-)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.0101 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.013 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.013 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.017 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.017 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.018 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.018 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.018 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	H1048 cells		CVCL_1453
Experiment 2 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.022 nM	High B7H3 expression (B7H3 +++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Minimally invasive lung adenocarcinoma	H358 cells		CVCL_1559
Experiment 3 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.291 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung papillary adenocarcinoma	H441 cells		CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Negative B7H3 expression (B7H3-)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01807 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on BT474
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02319 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on SKBR3
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03613 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on MCF-7
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2457 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on HCC1569
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 5 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3206 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on MDA-MB-468
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 6 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.6905 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on NCI-N87
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 7 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.9462 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on JIMT-1
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.019 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.019 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.021 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.022 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.022 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.023 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.023 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.024 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.0265 nM	Positive CD34 expression ( CD34+++/++)
Method Description	Primary human CD34+ cells were purchased from STEMCELL technologies (Vancouver, BC, Canada). The cells were obtained using Institutional Review Board (IRB)-approved consent forms and protocols. The steady-state human bone marrow CD34+ cells (3 donors, STEMCELL technologies) or purified mobilized CD34+ cells from two healthy rhesus macaques were cultured (2500 cells/well in 384-well plate) in serum-free StemSpan SFEM media (45 ul, STEMCELL Technologies) supplemented with 100 ng/ml each of Interleukin 6 (IL-6), fms-related tyrosine kinase 3 ligand (FLT3L), and thrombopoietin (TPO). Escalating doses of CD117-ADC as well as IgG isotype control-conjugated ADC were added (5 ul ADC added to 45 ul cells). After 6 days of culture, the number of viable CD34 + CD90+ cells were evaluated by flow cytometry using 7-Aminoactinomycin D (7-AAD as a viability marker, Biolegend, San Diego, CA, USA), CD34 BV785 (clone 561, BioLegend), and CD90 APC (Clone 5E10, BioLegend) detection antibodies. Cells were acquired on a BD Celesta Instrument and analyzed with FloJo. The EC50 and EC90 values were calculated with GraphPad Prism software.    Click to Show/Hide
In Vitro Model	Normal	Rhesus CD34+ cells		Macaca mulatta
Experiment 2 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.0521 nM	Positive CD34 expression ( CD34+++/++)
Method Description	Primary human CD34+ cells were purchased from STEMCELL technologies (Vancouver, BC, Canada). The cells were obtained using Institutional Review Board (IRB)-approved consent forms and protocols. The steady-state human bone marrow CD34+ cells (3 donors, STEMCELL technologies) or purified mobilized CD34+ cells from two healthy rhesus macaques were cultured (2500 cells/well in 384-well plate) in serum-free StemSpan SFEM media (45 ul, STEMCELL Technologies) supplemented with 100 ng/ml each of Interleukin 6 (IL-6), fms-related tyrosine kinase 3 ligand (FLT3L), and thrombopoietin (TPO). Escalating doses of CD117-ADC as well as IgG isotype control-conjugated ADC were added (5 ul ADC added to 45 ul cells). After 6 days of culture, the number of viable CD34 + CD90+ cells were evaluated by flow cytometry using 7-Aminoactinomycin D (7-AAD as a viability marker, Biolegend, San Diego, CA, USA), CD34 BV785 (clone 561, BioLegend), and CD90 APC (Clone 5E10, BioLegend) detection antibodies. Cells were acquired on a BD Celesta Instrument and analyzed with FloJo. The EC50 and EC90 values were calculated with GraphPad Prism software.    Click to Show/Hide
In Vitro Model	.	Human CD34+ cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.027 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.027 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.028 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.028 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.028 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.07 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75
Experiment 4 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.13 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.15 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75
Experiment 4 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.39 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.06 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.09 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75
Experiment 4 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.15 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.05 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532
Experiment 4 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.11 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.036 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03678 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04644 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04657 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.118 nM	Moderate XXX expression (XXX++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 5 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2095 nM	Low HER2 expression (HER2+)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Invasive breast carcinoma of no special type	MDA-MB-175 cells		CVCL_1400
Experiment 6 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.345 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.038 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	H1048 cells		CVCL_1453
Experiment 2 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.074 nM	High B7H3 expression (B7H3 +++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Minimally invasive lung adenocarcinoma	H358 cells		CVCL_1559
Experiment 3 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.245 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung papillary adenocarcinoma	H441 cells		CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Negative B7H3 expression (B7H3-)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03982 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on BT474
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04299 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on SKBR3
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.09942 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on MCF-7
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.778 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on HCC1569
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 5 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.413 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on MDA-MB-468
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 6 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.266 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on JIMT-1
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 7 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	13.86 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on NCI-N87
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.138 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.405 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532
Experiment 4 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.423 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 5 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.195 nM	Moderate XXX expression (XXX++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 6 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.635 nM	Low HER2 expression (HER2+)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Invasive breast carcinoma of no special type	MDA-MB-175 cells		CVCL_1400

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.06 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75
Experiment 4 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.81 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.31 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.042 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.043 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.048 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04926 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04987 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.06349 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.137 nM	Moderate XXX expression (XXX++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 5 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2628 nM	Low HER2 expression (HER2+)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Invasive breast carcinoma of no special type	MDA-MB-175 cells		CVCL_1400
Experiment 6 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.346 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.05 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.05 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.12 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Mouse melanoma	B16F10 cells		CVCL_0159
Experiment 3 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	98.13 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Malignant tumors of the mouse pulmonary system	LLC cells		CVCL_5653

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.05 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.19 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.75 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75
Experiment 4 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	23.48 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.067 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.07 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.91 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Mouse melanoma	B16F10 cells		CVCL_0159

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.072 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.075 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.076 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.08 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.082 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.085 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.09345 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on BT474
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1937 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on SKBR3
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.8554 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on MCF-7
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.6 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on HCC1569
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 5 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.47 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on JIMT-1
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 6 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12.09 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on MDA-MB-468
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.117 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.158 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.762 nM	Moderate XXX expression (XXX++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.106 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.237 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.334 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532
Experiment 4 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.623 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 5 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20.08 nM	Low HER2 expression (HER2+)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Invasive breast carcinoma of no special type	MDA-MB-175 cells		CVCL_1400
Experiment 6 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	26.42 nM	Moderate XXX expression (XXX++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.108 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.119 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1326 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 2 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1788 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3432 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4904 nM	Low HER2 expression (HER2+)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Invasive breast carcinoma of no special type	MDA-MB-175 cells		CVCL_1400
Experiment 5 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.065 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.14 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	6.5 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Mouse melanoma	B16F10 cells		CVCL_0159

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.15 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.22 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Mouse melanoma	B16F10 cells		CVCL_0159

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.156 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.193 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.232 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.34 nM	Positive HER2 expression (HER2 +++/++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532
Experiment 5 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.946 nM	Moderate XXX expression (XXX++)
Method Description	This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.17 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.1 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.192 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	870.5 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.215 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.22 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.13 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.222 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.236 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.237 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.15 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.29 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	250.7 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Mouse melanoma	B16F10 cells		CVCL_0159

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	146.5 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Mouse melanoma	B16F10 cells		CVCL_0159

Experiment 1 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3709 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on NCI-N87
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.45 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on BT474
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	18.29 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on HCC1569
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 4 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	57.85 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on SKBR3
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.372 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.6 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.373 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3812 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.382 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.2 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[73]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.544 nM	Positive CD19 expression (CD19+++/++)
Method Description	Flow cytometry was used to evaluate the cell surface binding of ADC-1 to different cancer cell lines expressing CD19 endogenously and 293T cells transduced with full-length human CD19.
In Vitro Model	Adult B acute lymphoblastic leukemia	RS4;11 cells		CVCL_0093
Experiment 2 Reporting the Activity Date of This ADC					[73]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.928 nM	Positive CD19 expression (CD19+++/++)
Method Description	Flow cytometry was used to evaluate the cell surface binding of ADC-1 to different cancer cell lines expressing CD19 endogenously and 293T cells transduced with full-length human CD19.
In Vitro Model	B-lymphoblastic leukemia	SUP-B15 cells		CVCL_0103
Experiment 3 Reporting the Activity Date of This ADC					[73]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.939 nM	Positive CD19 expression (CD19+++/++)
Method Description	Flow cytometry was used to evaluate the cell surface binding of ADC-1 to different cancer cell lines expressing CD19 endogenously and 293T cells transduced with full-length human CD19.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC					[73]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.061 nM	Positive CD19 expression (CD19+++/++)
Method Description	Flow cytometry was used to evaluate the cell surface binding of ADC-1 to different cancer cell lines expressing CD19 endogenously and 293T cells transduced with full-length human CD19.
In Vitro Model	Diffuse large B-cell lymphoma germinal center B-cell type, Diffuse large B-cell lymphoma	OCI-LY19 cells		CVCL_1878

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.465 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.0 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.465 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.20 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.92 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.0 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.92 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.19 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.23 nM	Positive HER expression (HER+++/++)
Method Description	Cell viability was determined after incubation with compound JY201 or JY201b or control.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Half Maximal Effective Concentration (EC50)	75.55 nM	Low HER2 expression (HER2+)
Method Description	Cell viability was determined after incubation with compound JY201 or JY201b or control.
In Vitro Model	Lung adenocarcinoma	HCC-827 cells		CVCL_2063
Experiment 3 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.29 ug/mL	Positive HER expression (HER+++/++)
Method Description	Cell viability was determined after incubation with compound JY201 or JY201b or control.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.365 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.18 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.955 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.1 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.8 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.117 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.0 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.117 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.21 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.95 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[75]
Efficacy Data	Half Maximal Effective Concentration (EC50)	77.81 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	Cells were plated into 96-well white round-bottom plates in RPMI-1640 medium supplemented with 10 % FBS. 24 h later, compounds were added to the 96-well plates. Following a 120h incubation period, cell viability was evaluated by a CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI, USA) and the EC50 values of each compound were determined.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.16 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Half Maximal Effective Concentration (EC50)	192.6 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Effective Concentration (EC50)	285.967 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.5 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ug/mL	Positive HER expression (HER+++/++)
Method Description	Cell viability was determined after incubation with compound JY201 or JY201b or control.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.6 ug/mL	Positive HER expression (HER+++/++)
Method Description	Cell viability was determined after incubation with compound JY201 or JY201b or control.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.44 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 34 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.48 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 26 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.51 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.53 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 36 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.54 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 38 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.55 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 19 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.55 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 42 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.6 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.72 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 23 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.72 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.74 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.78 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.79 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.8 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.81 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.82 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.84 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.86 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.92 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.95 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 15 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.03 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 13 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.05 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 29 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.08 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.26 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 19 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.4 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.49 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 44 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.69 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 20 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal Degradation Concentration (DC50)	0.045 nM
Method Description	The TMD8 wt cell line was cultured in media that is optimal for their growth at 5% CO 2, 37°C in a tissue culture incubator. Prior to seeding for the growth inhibition assay, the cells were split at least 2 days before the assay to ensure optimal growth density. On the day of seeding, suspension cells were harvested. Cell viability and cell density were determined using a cell counter (Vi-Cell XR Cell Viability Analyzer, Beckman Coulter). Cells with higher than 85% viability were seeded in white clear bottom 96-well TC treated plates (Corning cat. #3903). Cells were seeded at a density of 75,000 cells per well in 70 uL of standard growth media. Plates were incubated at 5% CO 2, 37°C overnight in a tissue culture incubator. On the day of dosing, all ADCs and low molecular weight payloads were prepared at 8X in standard growth media. The prepared treatments were added to the cells, resulting in final concentrations of 9.92e-6 - 100 nM and a final volume of 80 uL per well. Each drug concentration was tested in duplicates. Plates were incubated at 5% CO 2, 37°C for 48 hours in a tissue culture incubator. After 48 hours, cells were lysed with 80 uL of freshly prepared lysis buffer (10X Millipore RIPA Lysis Buffer + 0.5M EDTA + 1x Roche cOmpleteTM Protease Inhibitor Cocktail EDTA-free tablet, diluted in ddH 2O to 2X). Cells were resuspended and incubated on ice for 10 minutes. Lysates were stored until further use at -80°C. Prior to running the assay, MULTI-ARRAY 96 Plate Pack, SECTOR Plates (MSD, L15XA-3) were coated with 50 uL/well of a BTK (D3H5) Rabbit mAb (Cell Signaling Technology, 8547BF) at 1 ug/mL diluted in PBS overnight at 4°C. The next day, MSD plates were washed 3 times with 300 uL/well of PBS + 0.05% Tween. Plates were then blocked with 150 uL/well of PBS + 5% BSA buffer, shaking at 450 rpm for 1 hour at room temperature. Plates were then washed 3 times with 300 uL/well of PBS + 0.05% Tween. Each lysate sample was added to the MSD plates at 25 uL/well, shaking at 450 rpm for 2 hours at room temperature. Plates were then washed 3 times with 300 uL/well of PBS + 0.05% Tween. A Sulfo-tag purified mouse anti-human BTK antibody (BD, clone 53, 624084) was diluted to 0.5 ug/mL and 25 uL was added to each well. Plates were shaken at 450 rpm for 1 hour at room temperature. Plates were then washed 3 times with 300 uL/well of PBS + 0.05% Tween. MSD Read Buffer T (4x) (MSD, R92TC-1) was diluted to 2X with ddH 2O and 150 uL was added to each well. Plates were immediately read on an MSD Sector 600 Imager. To evaluate the effect of the drug treatments, signal levels from wells containing untreated cells (100% viability) were used to normalize treated samples. A variable slope model was applied to fit a nonlinear regression curve to the data in GraphPad PRISM version 10 software. GI50 and Amax values were extrapolated from the resultant curves.    Click to Show/Hide
In Vitro Model	Diffuse large B-cell lymphoma, Diffuse large B-cell lymphoma activated B-cell type	TMD8 cells (wt)		CVCL_A442

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal Degradation Concentration (DC50)	0.048 nM
Method Description	The TMD8 wt cell line was cultured in media that is optimal for their growth at 5% CO 2, 37°C in a tissue culture incubator. Prior to seeding for the growth inhibition assay, the cells were split at least 2 days before the assay to ensure optimal growth density. On the day of seeding, suspension cells were harvested. Cell viability and cell density were determined using a cell counter (Vi-Cell XR Cell Viability Analyzer, Beckman Coulter). Cells with higher than 85% viability were seeded in white clear bottom 96-well TC treated plates (Corning cat. #3903). Cells were seeded at a density of 75,000 cells per well in 70 uL of standard growth media. Plates were incubated at 5% CO 2, 37°C overnight in a tissue culture incubator. On the day of dosing, all ADCs and low molecular weight payloads were prepared at 8X in standard growth media. The prepared treatments were added to the cells, resulting in final concentrations of 9.92e-6 - 100 nM and a final volume of 80 uL per well. Each drug concentration was tested in duplicates. Plates were incubated at 5% CO 2, 37°C for 48 hours in a tissue culture incubator. After 48 hours, cells were lysed with 80 uL of freshly prepared lysis buffer (10X Millipore RIPA Lysis Buffer + 0.5M EDTA + 1x Roche cOmpleteTM Protease Inhibitor Cocktail EDTA-free tablet, diluted in ddH 2O to 2X). Cells were resuspended and incubated on ice for 10 minutes. Lysates were stored until further use at -80°C. Prior to running the assay, MULTI-ARRAY 96 Plate Pack, SECTOR Plates (MSD, L15XA-3) were coated with 50 uL/well of a BTK (D3H5) Rabbit mAb (Cell Signaling Technology, 8547BF) at 1 ug/mL diluted in PBS overnight at 4°C. The next day, MSD plates were washed 3 times with 300 uL/well of PBS + 0.05% Tween. Plates were then blocked with 150 uL/well of PBS + 5% BSA buffer, shaking at 450 rpm for 1 hour at room temperature. Plates were then washed 3 times with 300 uL/well of PBS + 0.05% Tween. Each lysate sample was added to the MSD plates at 25 uL/well, shaking at 450 rpm for 2 hours at room temperature. Plates were then washed 3 times with 300 uL/well of PBS + 0.05% Tween. A Sulfo-tag purified mouse anti-human BTK antibody (BD, clone 53, 624084) was diluted to 0.5 ug/mL and 25 uL was added to each well. Plates were shaken at 450 rpm for 1 hour at room temperature. Plates were then washed 3 times with 300 uL/well of PBS + 0.05% Tween. MSD Read Buffer T (4x) (MSD, R92TC-1) was diluted to 2X with ddH 2O and 150 uL was added to each well. Plates were immediately read on an MSD Sector 600 Imager. To evaluate the effect of the drug treatments, signal levels from wells containing untreated cells (100% viability) were used to normalize treated samples. A variable slope model was applied to fit a nonlinear regression curve to the data in GraphPad PRISM version 10 software. GI50 and Amax values were extrapolated from the resultant curves.    Click to Show/Hide
In Vitro Model	Diffuse large B-cell lymphoma, Diffuse large B-cell lymphoma activated B-cell type	TMD8 cells (wt)		CVCL_A442

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Partial Response (PR)	15.90 33.30 %
Patients Enrolled	Patients with platinum-resistant ovarian cancer (OC), metastatic triple negative breast cancer (TNBC) and received median 3 prior regimens.
Administration Dosage	0.15, 0.17, 0.18 mg/kg day1 and day15; q28d.
Related Clinical Trial
NCT Number	NCT04740398	Clinical Status	Phase 1
Clinical Description	A phase 1a/1b, open-label, multi-center, first in human and expansion study to assess the safety, tolerance, and pharmacokinetics of the novel antitumor agent CBP-1008 in patients with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[79]
Patients Enrolled	Metastatic breast cancer.
Administration Dosage	1.00 mg/kg.
Related Clinical Trial
NCT Number	NCT05261269	Clinical Status	Phase 1
Clinical Description	A dose-escalation study of the safety and pharmacology of dan-222 in subjects with metastatic breast cancer.

Experiment 1 Reporting the Activity Date of This ADC					[80]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 9.96%
Method Description	Ceralasertib=25 mg/kg.
In Vivo Model	Colon cancer CDX model
In Vitro Model	Colon cancer	HCT 116 cells		CVCL_0291
Experiment 2 Reporting the Activity Date of This ADC					[80]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 42.76%
Method Description	Ceralasertib=25 mg/kg.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[80]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 56.70%
Method Description	CBX-12=5 mg/kg.
In Vivo Model	Colon cancer CDX model
In Vitro Model	Colon cancer	Colon cancer cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[80]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.32%
Method Description	CBX-12=10 mg/kg.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 5 Reporting the Activity Date of This ADC					[80]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.22%
Method Description	Ceralasertib=25 mg/kg + CBX-12=5 mg/kg.
In Vivo Model	Colon cancer CDX model
In Vitro Model	Colon cancer	Colon cancer cells		Homo sapiens
Experiment 6 Reporting the Activity Date of This ADC					[80]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.40%
Method Description	Ceralasertib=25 mg/kg + CBX-12=10 mg/kg.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062